 
I8F-MC-GPHH(f) Clinical Pharmacology Protocol  
  Eﬀect of Tirzepa�de on Energy Intake and Appe�te -and Reward -Related Brain Areas in 
Overweight/Obese Subjects: A Placebo -Controlled 6 -Week Study With Func�onal MRI  
 
 
[STUDY_ID_REMOVED]   Approval Date: 08-Oct-202 1 
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 1
LY3298176Protocol I8F-MC-GPHH (f)
Effect of Tirzepatide on Energy  Intake andAppetite -and 
Reward -Related Brain A reas in Overweight/Obese 
Subjects:  A  Placebo- Controlled 6 -Week Study  with 
Functional MRI
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distri buted to persons not involved in the clinical investigation of 
tirzepatide (LY3298176 ), unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries.
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries .  
Tirzepatide (LY3298176 )
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Clinical Pharmacology Protocol Electronically Signed and Approved by Lilly: 31 Jan uary
2020
Amendm ent (a) Electronically Signed and Approved by Lilly : 03 Mar ch2020
Amendm ent (b) Electronically Signed and Approved by Lilly : 30 April 2020
Amendm ent (c) Electronically Signed and Approved by Lilly: 02 June 2020
Amendm ent (d) Electronically Signed and Approved
by Lilly : 11 December 2020
Amendm ent (e) Electronically Signed and Approved by Lilly: 02 February 2021
Amendm ent (f) Electronically Signed and Appr oved by Lilly on approval date provided 
below.
Approval Date: 08-Oct-2021 GMT
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 2
LY3298176Table of Contents
Effect of Tirzepatide on Energy Intake andAppetite -and 
Reward -Related Brain Areas in Overweight/Obese Subjects:  
A Placebo- Controlled 6 -Week Study  with Functional MRI
Section Page
Protocol  I8F-MC-GPHH(f) Effect of Tirzepat ide on Energy Intake and 
Appet ite-and Reward -Related Brain Areas in Overweight/Obese 
Subjects:  A Placebo -Controlled 6- Week Study  with Funct ional MRI .................................1
Table of Contents ........................................................................................................................ 2
1. Protocol  Synopsi s................................................................................................................ 8
2. Schedule of Act ivities....................................................................................................... 10
3. Introduction ...................................................................................................................... 18
3.1. Study  Rati onale............................................................................................................ 18
3.2. Background .................................................................................................................. 18
3.3. Benefit/Risk Assessment .............................................................................................. 20
4. O bject ives and Endpo ints.................................................................................................. 22
5. Study  Design ..................................................................................................................... 24
5.1. Overall Design ............................................................................................................. 24
5.2. Number of Parti cipants .................................................................................................27
5.3. End of Study  Definit ion............................................................................................... 27
5.4. Scientific Rationale for Study  Design ........................................................................... 27
5.5. Justification for Dose ................................................................................................... 28
6. Study  Popul ation............................................................................................................... 30
6.1. Inclusio n Cri teria.......................................................................................................... 30
6.2. Exclu sion Criteria........................................................................................................ 33
6.3. Lifest yle and Dietary Requirements .............................................................................. 37
6.3.1. Meals and Dietary  Restri ctions............................................................................. 37
6.3.2. Caffeine, Alcoho l, and Tobacco ........................................................................... 37
6.3.3. Activity................................................................................................................ 37
6.4. Screen Failures ............................................................................................................. 37
7. Treatment .......................................................................................................................... 38
7.1. Treatment Administered ............................................................................................... 38
7.1.1. Packaging and Labeling ....................................................................................... 39
7.2. Method of Treatment Assignment ................................................................................ 39
7.2.1. Selection and Timing o f Doses ............................................................................. 39
7.3. Blinding ....................................................................................................................... 40
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 3
LY32981767.4. Dose Modificat ion........................................................................................................ 40
7.4.1. Speci al Treatm ent Consi derat ions........................................................................ 40
7.4.1.1. Management of Subjects with Gastrointestinal Symptoms .............................. 40
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 41
7.6. Treatment Compliance .................................................................................................41
7.7. Concomitant Therapy ................................................................................................... 41
7.8. Treatment after the End of the Study ............................................................................ 42
8. Discontinuati on Cri teria .................................................................................................... 43
8.1. Discontinuati on from Study  Treatm ent......................................................................... 43
8.1.1. Perm anent Discont inuat ion from Study Treatment ............................................... 43
8.1.2. Discontinuati on of  Inadvertent ly Enrolled Subjects .............................................. 44
8.2. Discontinuati on from the Study .................................................................................... 44
8.3. Subjects Lost to Follow -up........................................................................................... 44
9. Study  Assessments and Procedures ................................................................................... 45
9.1. Efficacy Assessments ................................................................................................... 45
9.1.1. Appet ite and Eating Behavior Assessments .......................................................... 45
9.1.2. Neuroimaging Assessments .................................................................................. 46
9.1.3. Horm one and Metabo lite Assessments .................................................................47
9.2. Adverse Events ............................................................................................................ 47
9.2.1. Serious Adverse Events ........................................................................................ 48
9.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 49
9.2.2. Adverse Events of Special Interest ....................................................................... 49
9.2.2.1. Hypoglycemia ................................................................................................ 49
9.2.2.2. Pancreat itis..................................................................................................... 50
9.2.2.3. Thyroid Malignancies and C -Cell Hyperplasia ................................................ 51
9.2.2.4. Hypersensi tivity Events .................................................................................. 52
9.2.2.5. Inject ion-Site Reacti ons.................................................................................. 52
9.2.2.6. Hepatobiliary  Disorders .................................................................................. 53
9.2.2.7. Severe Gastrointestinal Adverse Events .......................................................... 53
9.2.2.8. Acute Renal Events ........................................................................................ 53
9.2.3. Com plaint Handling ............................................................................................. 53
9.3. Treatment of Overdose .................................................................................................53
9.4. Safety........................................................................................................................... 53
9.4.1. Laboratory  Test s.................................................................................................. 53
9.4.2. Vital Signs ........................................................................................................... 54
9.4.3. Body  Weight and Waist Circumference ................................................................ 54
9.4.4. Electrocardiograms .............................................................................................. 54
9.4.5. Physical Examinat ions......................................................................................... 55
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 4
LY32981769.4.6. Suicidal  Ideat ion Assessment ............................................................................... 55
9.4.7. Safety Moni toring ................................................................................................ 55
9.4.7.1. Hepati c Safet y................................................................................................ 56
9.5. Pharmacokinet ics......................................................................................................... 58
9.5.1. Bioanalysis ........................................................................................................... 58
9.6. Pharmacodynamics ...................................................................................................... 58
9.6.1. Immunogenicit y Assessments .............................................................................. 58
9.7. Genet ics....................................................................................................................... 59
9.8. Biomarkers ................................................................................................................... 59
9.9. Heal th Economics ........................................................................................................ 60
9.10. Passiv e Detecti on of  Eating Act ivity............................................................................ 60
10. Statistical Considerations and Data Analysis ..................................................................... 61
10.1. Sample Si ze Determinat ion.......................................................................................... 61
10.2. Popul ations for Analyses .............................................................................................. 61
10.2.1. Study  Parti cipant Disposit ion............................................................................... 61
10.2.2. Study  Parti cipant Characterist ics.......................................................................... 61
10.2.3. Treatment Compliance ......................................................................................... 61
10.3. Statistical Analyses ...................................................................................................... 61
10.3.1. Safety Analyses .................................................................................................... 62
10.3.1.1. Clinical Evaluation of Safet y.......................................................................... 62
10.3.1.2. Statistical Evaluat ion of Safet y....................................................................... 62
10.3.2. Pharmacokinet ic Analyses .................................................................................... 62
10.3.2.1. Pharmacokinet ic Parameter Estimat ion........................................................... 62
10.3.2.2. Pharmacokinet ic Statistical Inference ............................................................. 62
10.3.3. Pharmacodynamic Analyses ................................................................................. 62
10.3.3.1. Pharmacodynamic Parameter Estimation ........................................................ 62
10.3.3.2. Pharmacodynamic Statistical Inference ........................................................... 63
10.3.4. Evaluat ion of Immunogenicit y............................................................................. 63
10.3.5. Interim Analyses .................................................................................................. 64
10.3.6. Exploratory  Analysis for Motion Sensor Modeling ............................................... 64
11. References ........................................................................................................................ 65
12. Appendices ....................................................................................................................... 70
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 5
LY3298176List of Tables
Table Page
Table GPHH.1. Objectives and Endpo ints....................................................................... 22
Table GPHH.2. Study  Treatm ents and Dose Escalat ion................................................... 38
Table GPHH.3. Details o f Buffet Meal ............................................................................ 81
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 6
LY3298176List of Figures
Figure Page
Figure GPHH.1. Illustrati on of  study  design for Protocol I8F -MC-GPHH. ........................ 26
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 7
LY3298176List of Appe ndices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 71
Appendix 2. Clinical Laboratory  Tests ........................................................................ 76
Appendix 3. Study  Governance, Regulatory  and Ethi cal Considerati ons..................... 77
Appendix 4. Blood Sam pling Summary ...................................................................... 80
Appendix 5. Pharmacodynamic Assessments .............................................................. 81
Appendix 6. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y............ 89
Appendix 7. Pancreat ic Monitoring ............................................................................ 91
Appendix 8. Reco mmended Laboratory Test ing for Hypersensi tivity Events .............. 93
Appendix 9. Protocol  Amendment I8F -MC-GPHH(f) Summary - Effect of 
Tirzepati de on Energy  Intake and Appet ite-and Reward -Related 
Brain Areas in Overweight/Obese Subjects:  A Placebo -Controlled 
6-Week Study  with Funct ional MRI ....................................................... 95
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 8
LY32981761.Protocol Synopsis
Title of Study:
Effect of Tirzepatide on Energy Intake andAppetite -and Reward -Related Brain Areas in Overweight/Obese 
Subjects:  A Placebo -Controlled 6-Week Study with Functional MRI
Rationale:
Tirzepatide (LY3298176) is a long- acting, dual agonist that binds to the glucose -dependent insulinotropic 
polypeptide (GIP) receptor (GIPR) and the glucagon -like peptide -1 (GLP -1) receptor (GLP -1R).  The available 
preclinical and clinical data indicate that simultaneous stimulation of the se receptors may enhance insulin secretion, 
improve insulin sensitivity, and reduce body weight beyond the effect of selective GLP -1R stimulatio n.  
Study I8F-MC -GPHH (GPHH) is a Phase 1 study consisting of a 6-week treatment period, designed to examine the
effect of tirzepatide on energyintake, and central reward and appetite circuits compared with placebo to further 
understand the mechanisms involved in body weight reduction .
Objectives/Endpoints:   
Objectives Endpoints
Primary
To compare the effect of 5-mg tirzepatide versus 
placebo, at Week 3 on energyintake in a clinical 
setting.Change f rom baseline in energy intake (kcal) as 
assessed by ad libitum food intake test
Secondary
To compare the effect of 5-mg tirzepatide versus 
placebo, at Week 3 on:
Parameters of c entral reward and appetite circuits 
in the fasting state using BOLD fMRIChange f rom baseline in BOLD fMRI activation 
to images of highly  palatable food (high fat -high 
sugar and high fat -high carbohydrate) during the 
fasting state in the brain reward areas (insula, 
medial fro ntal gy rus, superior temporal gyrus, 
precentral gyrus, cingulate gyrus)
Parameters of b ehavioral appetite assessments Change f rom base line in fasting and postprandial 
appetite VAS, and fasting FCI, FCQ -S, Eating 
Inventory , Power of Food Scale questionnaires
Abbreviations:  BOLD = blood oxygen ationlevel -dependent; FCI = Food Craving Inventory; FCQ -S= Food 
Craving Questionnaire -State ; fMRI = functional magnetic resonance imaging; VAS =visual analog scale .
Summary of Study Design: 
Study I8F -MC -GPHH is a Phase 1, multi center, randomized , partially blinded, placebo -controlled, parallel arm 
study , with a positive control , liraglutide, in overweight/obese subjects.  The primary objective of this study is to 
compare the effect of tirzepatide and placebo on energy intake, as assessed by ad libitum food intake test, after 
3weeks of treatment at a therapeutic dose of 5 mg (Week 3).  Secondary objectives will compare these treatment 
groups for parameters of central reward and appetite circuits at Week 3.  Additional exploratory objectives will 
assess the effect of 10-mg tirzepatide versus placebo on energy intake and parameters of central reward and appetite 
at Week 6 .  
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 9
LY3298176Further exploratory analysis will assess the e ffect of tirzepatide versus an approved GLP -1 receptor agonist,
liraglutide on energy intake and parameters of central reward and appetite signaling at Weeks 3 and /or 6.  
Liraglutide will also be used as a positive control for the neuroimaging assessments of appetite -and reward -related 
brain areas .  
Tirzepatide maintenance dose levels of 5, 10 ,and 15 mg are currently b eing evaluated in the Phase 3 program in 
T2DM and chronic weight management indicatio n; both 5 and 10 mg doses are expected to result in weight loss. 
Tirzepatide 10 mgand liraglutide 3 mg will be attained via step -wise dose escalation t o reduce the risk of 
gastrointestinal adverse events. Eligibility for this study will be assessed at screening (Visit 1) and confirmed at the 
beginning of the lead-inperiod (Visit 2).  
Treatment Arms and Planned Duration for an Individual Subject :
The study  will consist of the following periods:  approximately 5-week screening period; 5 - day lead -in period; 
6-week treatment period, and a 4-week safety follow - up period.  S ubjects will be randomized in a 1:1:1 ratio to 
placebo, tirzepatide, or liraglutide.  Investigators and subjects will be blinded to tirzepatide and placebo treatment; 
however, liraglutide treatment will be open -label, therefore the stud y is considered partially blinded.   The 
randomization will be stratified by baseline BMI (27 to <30 kg/m 2, 30 to <35 kg/m 2, and 35 to 50 kg/m 2).
Tirzepatide once -weekly (QW) dosing will start at 5 mg for 3 weeks followed by a dose escalation to 10 mg for 
3weeks.  Subjects will return to the Clinical Research Unit ( CRU )each week for the QW administration of 
tirzepatide or placebo.  
Liraglutide once -daily  (QD) dosing will start at 0.6 mg for 1 week followed by weekly step-wise dose escalations to
1.2, 1.8, and 2.4 mg, until a 3 mg QD dose is reached.  The 3 -mg dose of liraglutide will be maintained for 10days.  
Subjects will self -administer liraglutide at home in the evening .
Number of Subjects:
Up to 111subjects ( 37subjects per treatment arm) are plann ed to be randomized so that approximately 93subjects 
(31subjects per treatment arm) complete the study, assuming 15% discontinuation rate.
Statistical Analysis:
Safety analyses will be conducted for all enrolled subjects, whether or not they completed al l protocol requirements.   
Safety parameters that will be assessed include safety lab parameters (including tirzepatide anti-drug antibodies ), 
vital signs, treatment -emergent adverse events ( TEAEs ; including TEAEs of special interest), and serious adverse 
events ( SAEs ).  The parameters will be listed and summarized using standard descriptive statistics.
Pharmacodynamic (PD) analy ses will be conducted on data from all subjects who r eceive at least 1 dose of the 
investigational product and have evaluable data. The primary PD parameter for analysis is energy (kcal) intake, 
which will be analyzed using an analysis of covariance (ANCOVA) to compare the effect of tirzepatide versus 
placebo at Week 3 with terms, treatment, baseline BMI stratum, and baseline energy (kcal) intake as a covariate in 
the model . The response variable in the model will be the change from baseline to Week 3 in energy (kcal) intake , 
as assessed by ad libitum food intake test . The primary analysis will show least squares means of energy (kc al) 
intake by treatment and the treatment difference of tirzep atide versus placebo as well as standard error and 95% 
confidence interval.  All tests will be done at the 2-sided 0.05 α level, unless otherwise specified.
Additional exploratory analyses of th e data may be conducted as deemed appropriate.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 10
LY32981762.Schedule of A ctivities
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 11
LY3298176Study Schedule Protocol I8F-MC -GPHH :  Screening and Lead -in
Procedure Screen ing Lead -in Comments
Week of Treatment -5 to -2 -1
Visit 1 2 NA NA NA 3
Study Day -35 to -5 -4 -3 -2 -11 
(predose)
Screening Procedures
Informed c onsent XInformed consent will be performed before any 
other screening procedures .
Lifesty le interview XPerformed to ensure subjects understand what they 
will be doing and if they are capab le of meet ing
study demands.
Medical h istory , menstrual cycle 
assessmentXMenstrual cycle assessment performed in females 
only.
Drug an d alcohol screen XProcedures may be repeated throughout the study as 
deemed necessary by the investigator.
Physical examination /medical 
assessmentX X XFull physical examination at screening.  After 
screening, m edical assessment is performed to 
include medical review and targeted examination, 
as appropriate.
Height , weight, and BMI X X X Height and BMI at screening only.
Waist circumference X X
Vital signs (BP/PR/body temperature) X X XSee Section 9.4.2 for details.  Vital sign 
measurements whose nominal times are not listed 
in the schedule should be taken before PK samples 
scheduled on the same day.  
ECG s (single for safety) X XSee Section 9.4.3 for details.  Electrocardiograms 
must be recorded before collecting any blood 
samples using equipment available at the study site .  
Confirm inclusio n/exclusion criteria X X
C-SSRS (baseline/ screening form) + 
SHSF + SHFFXThe SHFF is required only if triggered by the 
SHSF, per instructions in the form. 
PHQ -9 X
Clinical Procedures
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 12
LY3298176Procedure Screen ing Lead -in Comments
Week of Treatment -5 to -2 -1
Visit 1 2 NA NA NA 3
Study Day -35 to -5 -4 -3 -2 -11 
(predose)
Outpatient visit at CRU X X XLead -in outpatient visit can occur anytime between 
Day -4 andDay-1.
Training on signs /symptoms of 
hypoglycemia and self-treatmentXTraining can be completed anytime during the 
lead-in period prior to dosing.  
Training on self -administration of the 
subcutaneous liraglutide injection XTraining can be completed anytime during the 
lead-in period prior to dosing.
Concomitant medication review X X X Review of concomitant medication and adverse 
event can occur anytime between Day -4 andDay -
1.Adverse event review X X X
Randomization X
Laboratory Tests
Safety l aboratorytests X XSeeAppendix 2 for details. Subjects will fast for at 
least 12 hours before allblood sample sare
collected.
Pregnancy t est X X XSeeAppendix 2 for details. Performed and results 
confirmed prior to MRI.
Hormones and metabolites for appetite 
and metabolism regulation in the 
fasting and postprandial statesXPlasma o r serum samples to be taken to measure 
ghrelin, glucagon, glucose, and triglycerides 
(fasting), insulin (fasting and postprandial), and 
PYY, active GIP, active GLP -1, pancreatic 
polypeptide, amy lin, and leptin (postprandial).  
Postprandial samples will be taken within 
approximately 60 minutes of completing a test 
lunch meal.
Appetite and Eating Behavior See Appendix 5 for details.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 13
LY3298176Procedure Screen ing Lead -in Comments
Week of Treatment -5 to -2 -1
Visit 1 2 NA NA NA 3
Study Day -35 to -5 -4 -3 -2 -11 
(predose)
Ad libitum food intake test at lunch 
(clinic -based), with appetite VASXAppetite VAS will be completed before and after 
the lunch test meal. During Lead -in period , ad 
libitu m food intake test at lunch can be done in 
between Day -4 and Day -1.
FCI, FCQ -S, Eating Inventory, BIS ,
and Power of Food Scale 
questionnairesXDuring Lead -in period ,questionnaires can be done 
in between Day -4 and Day -1in a fasted state
shortly  after arriving to the study site.
Retrospective appetite VAS X
Neuroimaging See Appendix 5 for details.
BOLD fMRI XDuring Lead -in period ,fMRI can be done in 
between Day -4 and Day -1in a fas ted state .
Diagnostics
PK sample XPK sample not required for subjects randomized to 
liraglutide treatment.
Immunogenicity X
Pharmacogenetic sample X
Nonpharmacogenetic stored samples X
Abbreviations :  BIS = Barratt Impulsiveness Scale; BMI = body mass index; BOLD = blood oxygen ation level dependent; BP = blood pressure; CRU = clinical research unit; C-
SSRS = Columbia -Suicide Severity Rating Scale; ECG =electrocardiogram; FCI = Food C raving Inventory ; FCQ -S = Food Craving Questionnaire -State; fMRI = functional 
magnetic resonance imaging ; GIP=glucose -dependent insulinotropic polypeptide ; GLP -1 = glucagon -like peptide 1; MRI = magnetic resonance imaging; 
PD=pharmacodynamics; PHQ -9 = Patient Health Questionnaire -9; PK=pharmacokinetics; PR = pulse rate; PYY =peptide YY; SHFF = Self -Harm Follow -Up Fo rm; SHSF 
= Self -Harm Supplementary Form; VAS =visual analog scale.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 14
LY3298176Study Schedule Protocol I8F -MC -GPHH :  Treatment Period
Procedure Treatment
Week of Treatment 1 2 3 4 5 6
Visit 3 4 5 6 7 8 9 10 11 NA
Study Day 1a8
± 115
± 116
± 117 to 21g
22
± 129
± 136
± 137
± 138-39
± 1
Clinical Procedures
Outpatient visit at CRU X X X X X X X X
Weight P P P P P
Waist circumference P P
Vital signs (BP/PR/body temperature) P P P P P P P P
ECG s (single safety)
Concomitant medication review X X X X X X X X X
Adverse event review X X X X X X X X X
Dose Administration
Tirzepatide/placebo b X X X X X X
Liraglutide c Liraglutide will be self-administered everyevening from Day 1 through Day 38
Laboratory tests
Safety l aboratorytests X
Pregnancy testhX X
Hormones and metabolites for appetite 
and metabolism regulation in the fasting 
and postprandial states dX X
Appetite and Eating Behavior
Ad libitum food intake test at lunch 
(clinic -based), with appetite VAS eX X
FCI, FCQ -S, Eating Inventory, BIS, and 
Power of Food Scale questionnairesX X
Retrospective appetite VAS X X
Neuroimaging
BOLD fMRI X X
Diagnostics
PK sample f P P P
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 15
LY3298176Procedure Treatment
Week of Treatment 1 2 3 4 5 6
Visit 3 4 5 6 7 8 9 10 11 NA
Study Day 1a8
± 115
± 116
± 117 to 21g
22
± 129
± 136
± 137
± 138-39
± 1
Immunogenicity P P
Nonpharmacogenetic stored samples P P
Abbreviations :  BIS = Barratt Impulsiveness Scale; BMI = body mass index; BOLD = blood oxygen ation level -dependent; BP = blood pressure; CRU = clinical research unit; 
ECG =electrocardiogram; FCI = Food C raving Inventory ; FCQ -S = Food Craving Questionnaire -State; fMRI = functional magnetic resonance imaging ; 
GIP =glucose -dependent insulinotropic polypeptide ; GLP -1 = glucagon -likepeptide 1; MRI = magnetic resonance imaging; NA=not applicable; P =predose; 
PD=pharmacodynamics; PK =pharmacokinetics; PR = pulse rate; PYY =peptide YY; VAS =visual analog scale.
a  Predose assessments on Day 1 are shown in the Screening/Lead -in S chedule of Activities. 
bTirzepatide or placebo will be administered in the CRU only by CRU staff , the mo rning after an overn ight fast of at least 12hours .  
cLiraglutide will be self-administered by the subject in the evenings while at home .  
dPlasma or serum samples to be taken to measure ghrelin , glucagon, glucose, and triglycerides (fasting), insulin (fasting and postprandial), and PYY, active GIP, 
active GLP-1, pancreatic polypeptide, amylin, and leptin (postprandial) .  Postprandial samples will be taken within approximately 60 minutes of completing a 
test lunch meal.
eAppetite VAS will be completed before and after the test meal.
fPK sample not required to be collected for subjects randomized to liraglutide treatment.
gAdverse event and concomitant medication review may be remotely assess edany time between Days 17 and21 if deemed necessary by the investigator .
h  Pregnancy test will be conducted prior to fMRI.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 16
LY3298176Study Schedule Protocol I8F -MC -GPHH :  Follow -up Period
Procedure Follow -upEarly 
TerminationComments
Week s Post-Final Dose 3 4 NA
Visit 12 NA 13 NA
Study Day
(Subjects Randomized to Tirzepatide/Placebo)59± 1 60 - 63 ± 1 64± 1 NA
Study Day 
(Subjects Randomized to Liraglutide)61± 1 62 - 65 ± 1 66± 1 NA
Clinical Procedures
Outpatient visit at CRU X X X
At-home assessment X
Weight and waist circumference X X
Vital signs (BP/PR/body temperature) X X
ECGs (single safety) X X
Concomitant medication review X X X
Adverse event review X X X
Physical examination X X
Laboratory tests
Safety l aboratorytests X XSeeAppendix 2 for details. Subjects will 
fast for at least 1 2hours before allblood 
sample sarecollected.
Pregnancy test X X
Appetite and Eating Behavior
Training on use of RFPM and SmartIntake ®app 
trainingX
Ad libitum food intake test at lunch (clinic -based) X XSee Appendix 5 for details.  Only test meal 
(lunch) is required to be completed on Visit 
13. S ubjects must be wearing a
wrist-
wearable device during the test meal s.
Ad libitum food intake assessment (free -living) XSee Appendix 5 for details.  Measured with 
the RFPM and SmartIntake app .  Subjects 
will complete this assessment at home.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 17
LY3298176Procedure Follow -upEarly 
TerminationComments
Week s Post-Final Dose 3 4 NA
Visit 12 NA 13 NA
Study Day
(Subjects Randomized to Tirzepatide/Placebo)59± 1 60 - 63 ± 1 64± 1 NA
Study Day 
(Subjects Randomized to Liraglutide)61± 1 62 - 65 ± 1 66± 1 NA
Other Efficacy/ PD Assessments
Provide subjects with w rist-wearable device and 
training on its useXSee Section 9.10for details .  
Passive eating activity  data collection via 
wrist-wearable deviceX X X See Section 9.10 for details .  
Return w rist-wearable device to CRU staff X X
Diagnostics
PK sample X XPK sample not required for subjects 
randomized to liraglutide treatment.
Immunogenicity X X
Abbreviations :  BP = blood pressure; CRU = clinical research unit; ECG =electrocardiogram; NA = not applicable; PD=pharmacodynamics; PK =pharmacokinetics; PR = pulse 
rate; RFPM =Remote Food Photography Method ©.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 18
LY32981763.Introduction
3.1. Study Rationale
Tirzepati de (LY3298176) is a l ong-acting, dual agonist that binds to the glucose -dependent 
insulinotropic polypept ide (GIP) receptor (GIPR) and the glucagon -like peptide -1 (GLP -1) 
receptor (GLP -1R).  The available preclinical and clinical data in dicate that simultaneous 
stimulat ion of these receptors may  enhance insulin secretion, improve insulin sensit ivity, and 
reduce body  weight bey ond the effect of select ive GLP -1R stimulat ion (Frias et al. 2018; 
Coskun et al. 2018) .  Study  I8F-MC-GPHH (GPHH) is a Phase 1 study  consist ing of a 6-week
treatm entperiod , 
designed to examine the effect of tirzepat ide on energy  intake, and central  
reward and appeti tecircuits com pared wi th placebo to further understand the mechanism 
involved in body  weight reducti on.
3.2. Background
Glucagon -like peptide 1is synt hesized and secreted fro m enteroendocrine L cells in the small 
and large intestine and is a well -characteri zed incretin horm one that potenti ates insu lin and 
reduces glucagon secretion in a glucose -dependent manner after meal ingest ion.GLP -1 exerts 
its insulinotropic act ion through dist inct G -protein -coupl ed receptors highly expressed on islet 
cells and in some non -islet cells.  For example, GLP -1Rsare expressed throughout the brain, in 
regions that control  glucose ho meostasis, gut motilit y, energy intake, aversive signaling, and 
cardi ovascular funct ion (Campbell and Drucker 2013 ; Farr et al. 2016).  Currently , there are 
approved GLP -1 receptor agon ists (GLP -1RAs) for the treatment of diabetes and obesit y.  
Glucose -dependent insulinotropic polypeptide is synt hesized and secreted by  enteroendocrine K 
cells in the proximal intest ine.  The GIPR is widely expressed in islet s, gut, adipose tissue, and 
brain.  GIP secretion is primarily regulated by nutrients, especially fats.  GIP is responsible for 
the majorit y of the insulinotropi c incret in effect in humans (Calanna et al . 2013; Nauck and 
Meier 2016; Nauck and Meier 2019
). GIP has important addit ional funct ions that are dist inct 
from GLP -1.  GIP prom otes gl ucagon secret ion at low blood glucose levels to augment 
endogenous glucose production.  It stimulates lipolysis and inhibits insulin -induced lipogenesis 
in human adipocy tes.  Although GIP si gnaling on body  weight regulat ion is neutral , 
co-administration of individual GIP and GLP -1 selective agonists as well as unimo lecular 
co-agonists has shown profound weight -lowering benefits that exc eed that of either agent alone 
(Finan et al. 2016).  Despite the observed effects of GIP, currently, no pharmaceut ical agents that 
are based on its structure and funct ion have been developed for treatment of metabo lic 
condi tions.  
Tirzepati de is a 39 -amin o-acid synt hetic pept ide wit h dual agonist icactivity at both the GIP and 
GLP -1 receptors. Its structure is based on the GIP sequence and includes a C20 fatty di -acid 
moiety (Coskun et al. 2018). It is administered once weekly ( QW)by subcutaneous (SC) 
inject ion.
Tirzepati de is being developed as a therapy  to improve glycemic control in adults with t ype 2 
diabetes m ellitus (T2DM), as an adj unct to di et and exercise .  Tirzepat ide is also being 
investigated for chronic weight m anagement andnonal coho lic steatohepatit is.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 19
LY3298176In a Phase 1 study  (Coskun et al . 2018) that included single -and mult iple-ascending dose (SAD, 
MAD) parts, tirzepat idehas been administered as a single SC dose up to 8 mg in healt hy 
subjects.  In the MAD part, higher doses up to 10 mg were attained in healt hy subjects via dose 
escalat ion.  In the same study , doses up to 15 mg were achieved in pat ients with T2DM via dose 
escalat ion.  In this study , gastrointestinal ( GI)adverse events (AEs) (nausea, vomit ing, di arrhea, 
abdo minal distensio n) and decreased appet ite were the most frequent ly reported events by both 
healt hy subjects and pat ients with T2DM and were dose related.   Most AEs were mild in 
severit y, a few were m oderate, and none were reported as severe.  During the SAD study , the 
high incidence of GI AEs, notably vo miting, were considered to be dose limit ing at the 8 -mg 
dose; therefore, the 5- mg dose was considered th e maximum tolerated dose (MTD) for a single 
dose.  A dose -dependent increase in heart rate was detected in both healt hy subjects and pat ients 
with T2DM who received tirzepat ide, similar to what was observed wit h select ive GLP -1RAs.  
Afew subjects experien ced transient elevations in lipase and/or amylase levels, but these 
laboratory  observat ionswere not associated with any  relevant clinical outcom es.
Once -weekly doses of 1, 5, 10, and 15 mg have been further investigated in a Phase 2 study  
(Frias et al . 2018).  Addi tionally,dose l evelsof 12 and 15 mg, attained using alternate 
dose-escalat ion schemes ,were invest igated in a 12 -week Phase 2 study (Frias et al . 2020).  
Doses above 5 mg of tirzepatide were attained via stepwise dose escalat ion.  R esults from the 
2Phase 2 studies demo nstrated that tirzepat
ide at doses between 5 and 15 mg provided clinically 
meaningful efficacy in lowering both glucose and body  weight .  Gastrointest inal-related AEs 
(nausea, di arrhea, vo miting) were the most frequently  reported AEs in Phase 2 studies.  The 
majorit y of the treatment -emergent adverse events (TEAEs) were mild or moderate in severit y.  
Treatment with tirzepat ide was associated with treatm ent-emergent anti -drug ant ibodies 
(TE-ADAs) in 40.7% in the 26-week Phase 2 study.  However, the presence of ant i-drug 
antibodies (ADAs) appeared to have no effect on the pharmacokinet ics(PK), safet y, or efficacy 
of tirzepat ide.  There were no other clinically relevant safet yobservat ions in the Phase 1 and 2 
studi es.
Tirzepati de terminal  half-life was estimated to be approximately 5 days, thus supporting a QW 
dosing regimen, with maximum observed drug concentration occurring 24 to 72 hours post -dose.
Glucagon -like peptide -1 receptor agonists have demo nstrated efficacy  in body  weight reduction.  
Liraglut ide (Saxenda ®) is the first agent fro m this cl ass that has been approved for the treatment 
of chronic weight managem ent, at a dose of 3 mg /day.  The following dose escalat ion to a 3 -mg 
dose i s recommended to mi tigate the risk of GI side effects ; 1 week at 0.6 mg once -daily  (QD), 
1week at 1.2 mg QD, 1 week at 1.8 mgQD, 1 week at 2.4 mgQD, f ollowed by 3.0mg QD 
onwards (Saxenda package insert 2018) . Commonly reported adverse react ions following 
liraglutide administration include GI disorders (e.g., nausea, diarrhea, const ipation, vomit ing), 
metabo lism and nutrit ion disorders (hypoglycemia in patients with T2DM, decreas ed appet ite), 
and nervous sy stem  disorders (e.g., headache) (Saxenda package insert 2018) .  
Studi es that investigated the mechanism o f action of  liraglutide have shown thatliraglut ide
induce sweight loss by reducing appet ite and energy intake, with no ef fect on energy expenditure
(van Can et al. 2014; Blundell et al . 2017).
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 20
LY3298176In Phase 1 and Phase 2 development, treatment with tirzepat ide has shown clinically meaningful 
effect on body  weightregul ation by  suppressing appeti te and reducing energy intake, but no data 
are available regarding the effects of tirzepat ide on brain act ivity related to different food cues.
In the literature, i t is well demo nstrated that GLP -1 affects central reward and appet itecircuit s of 
the brain in healthy lean and obese subjects as well as subjects with T2DM (van Bloemendaal et 
al. 2014; Farr et al . 2016; Hayes and Schmidt 2016) .  
Com pared wi th healt hy lean subjects, obese patients with T2DM and non-diabet icobese subjects 
showed increased brain responses to visual foodcues in appet ite-and reward -related brain 
regions (insula and amygdala).  Intravenous t reatment wi th a GLP -1 receptor agonist, exenat ide, 
reduced these brain responses which correl ated wi th reducti on in foodintake(van Bloemendaal 
et al. 2014) . This effectwas m ediated by  the GLP -1 receptor activat ion, as the 
exenatide -induced effects were inhibited by infusion of the GLP -1 receptor antagonist, exendin 
9-39 (van Bloemendaal et al. 2014). Similarly, treatment with liraglut ide has been shown to 
reduce br ain act ivation in response to highly desirable food images in the parietal cortex (Farr et 
al. 2016) as well as the insula and putamen (ten Kulve et al. 2016 ).Recent literature has 
proposed the reducing effect of liraglutide on brain activat ionmay be sh ort-term; at 5 weeks 
following dose escalat ion to 3 mg, treatment with liraglutide did not show different ia
l activations 
in response to food cues , com pared to pl acebo (Farr et al. 2019). These results warrant further 
investigat ions of how dual  GIPR/GLP -1Ragonism affects brain act ivation in response to visual 
food cues .
Study  GPHH i s designed to assess the effect of tirzepatide versus placebo on energy intake, 
assessed by  ad libi tum food intake test, as well as central  reward and appeti tecircuitsusing 
funct ional magnet ic resonance imaging (fMRI) under fasting condi tion.  The effect of liraglut ide 
versus tirzepat ide and placebo on energy  intake will be assessed as an exploratory object ive.  In 
addition, li raglut ide treatment will be used in the cu rrent study  as a posi tive control for 
neuro imaging assessments .  The study  is expected to provide important, new informat ion on 
feeding behavior associ ated wi th a dual GIP/GLP -1 receptor agonist treatment .
3.3. Benefit/Risk Assessment
The m ost comm on safet y issue wit h administration of tirzepatide was related to frequent 
reporting of decreased appet ite and GI side effects, most commo nly nausea, vomit ing, and 
diarrhea.  These GI events were generally mild in severit y, with few m oderate, and no severe 
events reported in Phase 1 studies.  Tirzepat ide triggered generat ion of ADAs in a subset of 
patients in Phase 2 tri als.  The presence of tirzepat ide ADA did not affect PK or 
pharmacodynamic (PD) parameters and was not associated with in creased incidence o f local or 
systemic hypersensit ivity AEs in Phase 1 and Phase 2 studies up to 26 weeks of exposure.  Based 
on these results, tirzepat ide ADA represents a low risk in exposed patients, but more data is 
needed for definit ive conclusio n on the frequency  and severi ty of possible side effects.  No other 
clinically relevant safet y concerns were i dentified in the dose range up to 15 mg, the highest dose 
investigated in Phase 1 and Phase 2 studies in T2DM patients, administered QW up to 26 weeks.
Findings to date indicate that the safet y profile for a dual GIP/GLP-1 receptor agonist is similar 
to the safet y profile of the select ive GLP -1RAs.  P otenti al risks, such as GI effects, acute 
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 21
LY3298176pancreat itis, increases in heart rate, and hypoglycemic events are consistent with the risks 
associ ated wi th current ly available GLP -1RAs , including liraglut ide, the positive control in this 
trial.  To mit igate the risk of GI adverse events , the target tirzepat ide 10 m g andliraglut ide 3 mg 
doses will be attained via step- wise dose escal ation.  Based on the results of Phase 2 study 
(Friaset al. 2018 ), tirzepat idedoses of 5, 10 ,and 15 mg are expected to lead to meaningful body 
weight reducti on.  While 5 -mg tirzepati de can safely  be administered as a first dose ( i.e., the 
MTD in Study  GPGA ; Coskun etal. 2018 ), doses of 10 and 15 mg can be attained only via step 
wise dose escal ation to minimize the potential for GI adverse events.
Details on the management of the potenti alrisksare provided in Section7.4.1.1 (Management of 
Subjects with Gastrointest inal Symptoms) and Secti on9.2.2 (Adverse Eve nts of Special 
Interest) .  The monitoring plan for all AEs of special interest is included in this protocol, as well 
as treatm ent m easures.
Since Study GPHH will enroll subjects without diabetes, no self -monitoring of plasma glucose
(PG) is planned.  Consistent with the mechanism of action of incret ins, which are non -
secretagogues, severe hypoglycemia has not been reported in Phase 1 or Phase 2 trials that 
included healt hy subjects or patients with T2DM.  However, to mit igate the risk, th e subjects in 
this study  will be trained on signs and symptoms of hypoglycemia and self -treatm ent m easures.  
Secti on9.2.2.1 (Hypoglycemia) describes de finitions and criteria when diagnosing and 
categori zing an episode considered to be related to hy poglycemia , and provi des detailed 
inform ation concerning the management of hypoglycemia .  
There are several possible AEs associated with the planned procedure s in the study.  Amagnetic 
resonance imaging (MRI )scanner will be used to assess brain response patter ns to food and 
control  images (see Appendix 5 for more details).  Some level of claustrophobi a or di scomf ort 
may be experienced from staying in the fMRI scanner .
Although there is a possibilit y of weight loss associated with tirzepat ide treatment, s ubjects in 
Study GPHH are not expected to have direct healt h-related benefits due to the short duration of 
study  treatm ent.  The potential risks described above , which are also similarly reported in 
liraglutide,are considered clinically detectabl e,transient ,manageable , and associ ated wi thlow 
long-term health risks.  The routine clinical safet y monitoring procedures planned in this study  is 
considered sufficient to mit igate the possible risks .
More informat ion about the known and expect ed benefits, risks, serious adverse events (SAEs) 
and reasonably ant icipated AEs of tirzepat ide are to be found in the Investigator’s Brochure (IB).  
Inform ation on AEs expected to be related to the investigational product (IP) can be found in 
Secti on6 (Summary o f Data, Development Core Safet y Inform ation) of the IB.  Information on 
SAEs that are expected in the study  popul ation independent of drug exposure will be assessed by 
the sponsor i n aggregate, periodically during the course of the study , and can b e found in 
Secti on5 (Effects in Humans) of the IB .
More detailed informat ion about the known and expected benefits and risks of liraglut ide 
(Saxenda) may be found in the Package Insert or US Prescribing Information (USPI) .
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 22
LY32981764.Objectives and Endpoints
Table GPHH .1shows the object ives and endpoints of the study .
Table GPHH .1. Objectives and Endpoints
Objectives Endpoints
Primary
Tocompare the effect of 5-mg tirzepatide versus 
placebo, at Week 3, onenergy intake in a clinical 
setting.Change f rom baseline in energy intake (kcal) as 
assessed by ad libitum food intake test 
Secondary
Tocompare the effect of 5-mg tirzepatide versus 
placebo, at Week 3 on:
Parameters of c entral reward and appetite circuits 
in the fasting state using BOLD fMRIChange from baseline in BOLD fMRI activation 
to images of highly  palatable food ( high fat -high 
sugar and high fat -high carbohydrate )during the 
fasting state in the brain reward areas (insula, 
medial fro ntal gy rus, superior temporal gyrus, 
precentral gyrus, cingulate gyrus)
Parameters of b ehavioral appetite assessments Change f rom baseline in fasting and postprandial 
appetite VAS, and fasting FCI, FCQ -S, Eating 
Inventory, Power of Food Scale questionnaires
Exploratory
Tocompare the effect of 5-or 10 -mg tirzepatide versus 
placebo at Week 3 and/or Week 6 on:
Parameters of c entral reward and appetite circuits 
in the fasting state using BOLD fMRI ( Week 6 /10 
mg)Change f rom baseline in BOLD fMRI activation
to images of highly  palatable food ( high fat -high 
sugar and high fat -high carbohydrate )during the 
fasting state in the brain reward areas (insula, 
medial frontal gyrus, superior temporal gyrus, 
precentral gyrus, cingulate gyrus)
Parameters of b ehavioral appetite assessments
(Week 6 /10 mg )Change f rom baseline infasting and postprandial
appetite VAS, and fasting FCI, FCQ -S, Eating 
Inventory, Power of Food Scale questionnaires
Energy intake in a clinical setting (Week 6/10 mg) C hange f rom baseline in energy intake (kcal) as 
assessed by ad libitum food intake test
Parameters of central reward and appetite circuits 
in the fasting state using BOLD fMRI (Week 3 /5 
mgand Week 6/10mg)Change f rom baseline in BOLD fMRI activation 
to images of highly  palatable food ( high fat -high 
sugar and high fat -high carbohydrate )during
fasting state in the hippocampus, putamen, 
orbitofrontal cortex , and ventral striatum brain 
regio ns
Impulsivity (Week 3/5 mg and Week 6/10 mg ) Change f rom baseline in BISquestionnaire
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 23
LY3298176Appetite and metabolism regulati ng ho rmones and 
metabolites (Week 3/5 mg and Week 6/10 mg)Change f rom baseline in ghrelin , glucago n, 
glucose, and triglycerides (fasting), insulin (fasting 
and postprandial), and amylin,GIP, GLP-
1, leptin, 
pancreatic polypeptide, and PYY (postprandial)
Tocompare the effect of 5-and 10 -mg tirzepatide
versus liraglutide and liraglutide versus placebo at 
Week 3 and/ or Week 6 on:
Energy intake in a clinical setting (Week 3/5 mg 
and Week 6/10 mg )Changes from baseline in energy intake (kcal) as 
assessed by ad libitum food intake test 
Parameters of behavioral appetite assessments 
(Week 3/5 mg and Week 6/10 mg ) Change f rom baseline infasting and postprandial
appetite VAS, and fasting FCI, FCQ -S, Eating 
Inventory, Power of Food Scale questionnaires
Parameters of c entral reward and appetite circuits 
in the fasting state using BOLD fMRI ( Week 3/5 
mg and Week 6/10 mg )Change f rom baseline in BOLD fMRI activation
to images of highly  palatable food ( high fat -high 
sugar and high fat -high carbohydrate )during the 
fasting state in the brain reward areas (insula, 
medial fro ntal gy rus, superior tempora l gyrus, 
precentral gyrus, cingulate gyrus , hippocampus, 
putamen, orbitofrontal cortex, and ventral 
striatum)
Appetite and metabolism regulati ng ho rmones and 
metabolites (Week 3/5 mg and Week 6/10 mg )Change f rom baseline in ghrelin , glucago n, 
glucose, and triglycerides (fasting), insulin (fasting 
and postprandial), and amylin,GIP, GLP-1, leptin, 
pancreatic polypeptide, and PYY (postprandial)
To assess the safety and tolerability of tirzepatide. Adverse events
Safety laboratory parameters
Frequency of treatment -emergent 
anti-tirzepatide antibodies
Abbreviations: BIS = Barratt Impulsiveness Scale; BOLD = blood oxygen ationlevel -dependent; FCI = Food 
Craving Inventory; FCQ -S= Food C raving Questionnaire -State ; fMRI = functional magnetic resonance imaging ; 
GIP = glucose -dependent insulinotropic polypeptide; GLP -1 = glucagon -like peptide 1; PYY = peptide YY; VAS 
= visual analog scale.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 24
LY32981765.Study  Design
5.1. OverallDesign
This is a Phase 1, multicenter, randomized , partially blind ed, placebo -controlled, paralle l-arm 
study ,with a posi tive control , liraglut ide in overweight/obese subjects.  The primary object ive of 
this study  is to compare the effect of tirzepat ideand placebo on energy intake,as assessed by ad 
libitum food intake test , after 3 weeks of treatm entat a therapeutic dose of 5 m g (Week 3 ). 
Secondary  object ives will co mpare these treatment groups for parameters of central  reward and 
appeti te circuitsat Week 3 .Addit ional exploratory object ives will assess the effect of 10-mg 
tirzepat ide ver sus placebo on energy  intake and param eters of central  reward and appetite at 
Week 6 .  
Further exploratory  analysis will assess the effect of tirzepat ide versus liraglut ide, and li raglutide
versus placebo on energy  intake and parameters of central reward and appet ite signali ngat 
Weeks 3 and /or6.  
Liraglut ide will also be used as a posit ive control for the neuroimaging assessments of 
appeti te-
and reward- related brain areas .  
See Secti on5.4for details on study  design rati onale .  
Thestudy  will consist of 4 periods (see Secti on2, Schedule of Act ivities):
approximately 5-week screening period (Visit 1; Days -35 to - 5)
a 5-daylead-in period , including pre -dose assessments on Day  1(Visit s 2to 3)
o3 clinic alresearch unit [ CRU ]outpati ent visits
a 6-week treatment period (Visits 3to 11)
o9 CRU outpati ent visits
a 4-week safet y follow -up peri od(Visits 12 and 1 3)
o2 CRU outpatient visits 
The subject will sign the informed consent form (ICF) before any study  procedures are 
perform ed.  Eligibilit y will be assessed at screening (Visit 1) and confirmed during the lead -in 
period (Vi sit 2), when safet y laboratory  resul ts will  be available .  
Subjects will perform b
aseline assessments in the CRU prior to randomizat ion, according to the 
Schedule of Act ivities (Secti on2).  After the complet ion of all baseline procedures, subject s will 
be randomized in a 1:1:1 ratio to tirzepat ide,placebo, or liraglutide. Invest igators and subjects 
will be blinded to tirzep atide and placebo treatm ent; however, lir aglut ide treatment will be 
open -label, therefore the study  is considered partially blinded (see Section5.4).  The 
rando mizat ion will be stratified by baseline BMI ( 27 to <30 kg/m 2, 30 to <35 kg/m 2, and 35 to 
50 kg/m 2).
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 25
LY3298176Tirzepati deQW dosing will start at 5 mg for 3 weeks followed by a dose escalation to 10 mg for 
3 weeks.  Subjects will return to the CRU each week for the QW administration of tirzepat ide or 
placebo.
Liraglut ide QD dosing will start at 0.6 mg for 1 week fo llowed b y weekly  step-wise dose 
escalat ionsto 1.2, 1.8, and 2.4 mg, until a 3 mg QD dose is reached.   The 3 -mg dose of 
liraglutide will be maintained for 10 days.   Subjects will self -administer liraglut ide at home in 
the evening .  
Secti on2(Schedule of Act ivities) details all planned visits and procedures for this study .  After 
completion of the 6- week treatm ent peri od, subjects willattend 2 follow -up outpati ent visi ts at 
the CRU; approximately  3 and 4 weeks after the last dose of study  drug. The final follow-up 
visit will assess subject safet y,subjects will return the wearable device ,and subsequent ly 
complete each subject’s part icipation.
All subjec ts will  receive study  diaries where they  will be instructed to record relevant clinical 
inform ation,when outside of the CRU (e.g., AEs, concomitant medicat ions, details o f drug 
dosing , hypoglycaemia symptoms) .  
Figure GPHH. 1illustrates the study  design.   Study governance considerat ions are described in 
detail in Appendix 3 .
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 26
LY3298176Abbreviations: BOLD = blood oxygen ation level -dependent; fMRI = functional MRI; QD = once daily; QW = once weekly .  
Figure GPHH. 1. Illustration of study design for Protocol I8F -MC-GPHH.

I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 27
LY32981765.2. Number of Participants
Up to 111subjects (37subjects per treatment arm) may be enro lled to maximize the probabilit y 
that approximately 93subjects (31subjects per treatment arm) complete the study .  For purposes 
ofthis study , a subject completes the study  when all  scheduled procedures shown in the Schedule 
of Activities have been finished.
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on2) for the last subject.
5.4. Scientific Rationale for Study Design
Tirzepati detreatm ent is current ly being invest igated for chronic weight management, therefore 
overwei ght/obese subjects only  will be enrolled as the target populat ion.  In addit ion, 
overwei ght/obese subjects are expected to be more suscept ible to a potential weight reduction 
effect by  tirzepat ide and liraglut ide as co mpared to lean subjects.  Previous literature has 
confirmed obese subjects (body  mass index [BMI] ≥30kg/m 2) had increased brain responses to 
food cues in central reward
-and appetite -related brain regio ns, com pared to l ean subjects (BMI 
<25 kg/m 2) (van Bl oemendaal  et al . 2014).  To avoid the confounding effect of changes in 
glucose regul ation on energy intake, the study  will enroll  nondiabet ic subjects only.
Study  GPHH will emplo y a parallel -group desi gnto avoidthe confounding effects of the study  
treatm ents expected if a cross -over desi gn is used.  
The primary study  measure of the ad libitum food intaketestwas chosen as the most 
reproducible and clinically  relevant measure of energy  intake.  The sec ondary  study  measures, 
such as funct ional neuroimaging (blood ox ygenat ion level -dependent [BOLD] MRI) , parameters 
of appeti te,and eating attitudes and behavi ors, are expected to provide important additional data.  
All study  measures and m ethods of assessment are well validated and full yestablished in the 
medical literature as the parameters and methods relevant for objectives of Study  GPHH.  
Placebo has been chosen as the primary control treatment to assess whether any observed effects 
are treatme nt-related or simply  reflect the study  condi tions.  Liraglut ide(Saxenda ) has been
chosen as a neuro imaging positive control for GLP-1 pharmaco logy.  Liraglut ide (1.8 mg) has 
been shown to reduce brain activation 
in response to highly desirable food images in the parietal 
cortex (Farr et al. 2016) as well as the insula and putamen (ten Kulve et al. 2016).   The dose 
justificat ion for tirzepat ide and liraglutide is provided in Section 5.5(Justificat ion of Dose).
The timing of endpoint measurements (Week 3 and Week 6) was determined based on the effect 
of GLP -1 on brain centers and the time needed to escalate doses.   In addit ion, tirzepat idedoses 
of5-mg and 10 -mg have shown to result in clinically meaningful body  weightreducti on (Fri as et 
al. 2018).   Previous literature confirms liraglut ideeffects on central nervous sy stem activation 
were observed fo llowing 10 to 17 day s of treatm ent, where liragl utide dose was escalated weekly 
to 1.8 mg (Farr et al . 2016; ten Kulve et al. 2016) , supporting efficacy assessment sat Week 3 in 
the current study .Given the possibilit y that the effect of incret ins on brain activation is short 
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 28
LY3298176term (Farr et al. 2019) , theWeek 3 efficacy assessment of 5-mg tirzepati deversus placebo will 
be the primary  object ive. The influence of higher tirzepat idedoses, such as 10 mg ,on brain 
activit yis not y et understood , therefore efficacy assessment s in the current study will oc curat 
Week 6 (as exploratory  endpo ints),due to the need for dose escalation to attain a 10 -mg 
tirzepat idedose.  
In addit ion, efficacy  assessment sat Week 6 was chosen to observe the effect of tirzepat ideand 
liraglutide afterthedose-escalat ionregime ntoreach 10mgand 3 m g, respectively. 
The dosing of tirzepat ide will be double blinded and placebo -controlled in order to avoid bias in 
the collect ion and evaluat ion of data during its conduct.  Liraglutide dosing will be open label as 
blinding is not possible due to the QD dosing regimen .  In order to achieve the recommended 
liraglutide dose -escalat ion scheme, liraglut ide doses must be self -administered daily  in 
comparison to the weekly dosing of tirzepatide/placebo in the CRU .  
The rati onale for the sample size is provided in Secti on10.1 (Sam ple Si ze Determinat ion).
5.5. Justification for Dose
Tirzepati de m aintenance dose levels of 5, 10 ,and 15 mg are current ly being evaluated in the 
Phase 3 program for T2DM and chronic weight management indicat ion. Results from a Phase 2 
study  (Frias et al . 2020ha
veshown that in addit ion to the highest dose level o f 15 m g, tirzepati de 
dose l evels o f 5 and 10 m g also resul t in clinically meaningful body  weight reducti on.  
Weekly doses of tirzepati deranging fro m 0.25 to 8 mg have been studied in the single -ascending 
dose study, with MTD achieved at 5 m gwhen administered as a single dose . Dose levels o f 
10and15 m g were tol erated when administered via step -wise dose escalat ion (Frias et al. 2018; 
Coskun et al. 2018).  Tirzepati de 15 m g is predicted to m aintain an exposure mult iple of 1.6 to 
2.4to the no -observed -adverse -effect l evel doses in 6-mont h monkey and rat toxico logy studies, 
respectively .  Addit ional information can be found in the IB.
Tirzepati de dose sof 5 mg and 10 m g administered SCQW have been selected for invest igation 
in this study based on current toxico logy, and clinical da ta.  Do ses of liraglut ideQD f or 17 days 
(dose escal ated to 1.8 -mg)reduce dbrain act ivationin response to highly desirable food imag es
(Farr et al. 2016 ; ten Kulve et al. 2016). However , following 5- weeks of dosing with liraglut ide 
(dose escal ated to 3 -mg), 
different ialbrain act ivity in response to food cues , com pared to 
placebo, was not observed (Farr et al. 2019).  Therefore , doses of 5 -and 10 -mgtirzepat idehave 
been chosen in the current study  asthey can be attained in a reasonable durat ion,while provi ding 
an opportunit y to observe brain act ivity signals up to 6 weeks .
The ti rzepat idetreatment peri od will consist of a step- wise dose escalat ion where dosing will 
start at 5 m g QW for the first 3 weeks fo llowed by escalat ion to 10 mg QW at Week 4, fo llowed 
by rep eating administration of the 10 -mg dose at Week 5 and Week 6. Dosing will b e init iated at 
5mg and administered for 3 weeks before escalat ing to a 10-mg dose. This stepwi seincrement 
was selected based on cumulative understanding of safet y and GI tol erabilit y from Phase 1 and 2 
studi es.  Itis expected to minimize GI tolerabili ty concerns in this overwei ght/obese populat ion 
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 29
LY3298176by permitt ing adequate time for development of tolerance to GI events. Near steady -state 
exposures are expected to be attained wit hin 3 weeks of dosing at the 10 -mg dose level.
The final liraglut ide dose of 3mg is selected because it is the highest dose approved for the 
treatm ent of chroni c weight m anagement . Addit ionally , theliraglut ide dose of 1.8 m g at Week 3
shoul d resul t in sufficient exposure to act as the positive control in the current study (Farr et al . 
2016) .  The dose -escalat ion schedule of liraglut ide to be used in the current trial is consistent 
with the recommended dosing of marketed liraglutide (Saxenda package insert 201 8)and has 
been chosen to mit igate the risk o f GI AEs .
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 30
LY32981766.Study  Popu lation
Eligibilit y of subjects for the study  will be based on the results of screening medical history , 
physical examinat ion, vital signs, clinical laboratory tests, and electrocardiograms (ECGs).
The nature of any condit ions present at the time of the phy sical examinat ion and any preexist ing 
condi tions will  be docum ented.
Screening may occur within approximately 4 weeks prior to lead -in.  Eligible subjects will enter 
lead-in (Visit 2) approximately  4 days prior to randomizat ion.  Subjec ts who are not enrolled 
within 6weeks of screening may be subjected to addit ional medical assessment and/or clinical 
measurements to confirm their eligibilit y.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Subjects are eligible for inclusio n in the study  only if they  meet all  the f ollowing cri teria at 
screening:
Subject Characteristics
[1] are overwei ght/obese (BMI of 27kg/m 2to 50 kg/m 2, inclusive , and can 
complete MRI scans (see Exclusio n Criterion 8) , and non diabeti c male or 
female subjects, as determined by medical history ,physical examinat ion, and 
laboratory  assessments at screening ;  
[2] must be weight stable (no weight change o f >4kg) in the last 1 month;
[3] have safet y laboratory  test resul ts wi thin normal reference range or with 
abnorm alities deemed clinically  insignificant by  the invest igator;
[4] h ave venous access sufficient to allow for blood sampling as per the protocol;
[
5] m ale or female subjects between the ages of 18 to 6 5years, inclusive;
[5a] male subjects :
men, regardl ess of thei r fertility status, wi th nonpregnant wom an of 
childbearing potential (WOCBP) partners must agree to either remain 
abstinent (if this is their preferred and usual lifest yle) or use condoms 
plus1 addi tional highly  effect ive (less than 1% failure rate) method of 
contraception (such as co mbination oral contraceptives, implanted 
contraceptives, or intrauterine device) or effect ive method of 
contraception ,(such as diaphragms wit h spermicide or cervical sponge) 
for the durati on of  the study and for 5 half -lives of study  drug pl us 
90days, corresponding to 4 months after the last inject ion.  
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 31
LY3298176omen and thei r partners m ay choose to use a double -barrier method 
of contracepti on.  (Barri er protecti on methods wi thout concomi tant 
use of a spermicide are not an effect ive or acceptable method of 
contraception.  Thus, each barrier method must include use of a 
spermicide.  It should be noted however that the use of male and 
female condo ms as a double -barrier m ethod is not considered 
acceptable due to the high failure rate when these barrier methods 
are combined.)
operiodic abst inence (e . g., calendar, ovul ation, symptothermal, 
postovulat ion methods), declarat ion of abst inence just for the 
durati on of  a study , and wi thdrawal  are not acceptable methods of 
contracepti on.
men wi th pregnant partners should use condoms during intercourse for 
the duration of the study  and unt il the end of est imated relevant potential 
exposure in WOCBP ,which corresponds to 4 months following last 
inject ion.  
men m ust agree to refr ain fro m sperm  donati on for the durati on of  the 
study  and until their plasma concentrations are below the level that could 
resul t in a relevant potential exposure to a possible fetus, predicted to be 
4 months following l ast 
inject ion.
men who are in exclusively  same -sex relati onships (as thei r pref erred 
and usual lifest yle) are not required to use contraception.
[5b] female subjects :
women of childbearing potential who are abstinent (if this is co mplete 
abstinence, as their preferred and usual lifest yle) or in a same -sex 
relationship (as part of their preferred and usual lifest yle) must agree to 
either rem ain abst inent or stay in a same -sex rel ationship wit hout sexual 
relationships wi th males.  Peri odic abst inence (e .
g., calendar, ovul ation, 
symptothermal, post -ovulation methods), decl aration of abst inence just 
for the durati on of  a study , and wi thdrawal are not acceptable methods 
of contracepti on.
otherwise, WOCBP participating must a gree to use effect ive 
contraception, where at least 1 form is highly effective (less than 1% 
failure rate) , for the ent irety of the study .  Contracepti on m ust continue 
following co mpletion of IP administration for 30 days.
owomen of child bearing potenti al participat ing must test negative 
for pregnancy  prior to i nitiation of treatment as indicated by  a 
negat ive serum pregnancy test at the screening visit fo llowed by  a 
negat ive urine pregnancy test within 24hours pri or to exposure 
otwoforms of effective cont raception, where at least 1 form is 
highly  effect ive (less than 1% failure rate, such as combinat ion 
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 32
LY3298176oral contraceptives, implanted con tracepti ves or intrauterine 
devices) will be used.  Effect ive contraception (such as male or 
female condo ms with spermici de, di aphragms wit h spermicide or 
cervical sponges) may be used as the second therapy .  Barri er 
protecti on m ethods wi thout concomi tant use of a spermicide are 
not a reliable or acceptable method.  Thus, each barrier method 
must include use of a spermicide (that is, condom with spermicide, 
diaphragm  with spermicide, female condom with spermicide).  It 
shoul d be noted that the use of male and female condo ms as a 
doubl e barri er method i s not considered acceptable due to the high 
failure rate when these methods are combined.
oNot be breastfeeding
women who are not of childbearing potential may participate and 
include those who are:
oinfertile due to surgical sterilizat ion (hysterectomy, bilateral 
oophorectomy , or tubal  ligation), congenital ano maly such as 
mullerian agenesis, or
opostmenopausal –defined as eit her
i. awom an at l east 40years of age with an intact uterus, not 
on horm
one therapy , who has cessat ion of menses for at 
least 1 y ear without an al ternat ive medical cause, AND a 
follicle -stimulat ing horm one (FSH) ≥40 m IU/mL ; wom en 
in this category  must test negative in pregnancy  test pri or to 
study  entry
ii. awom an 55 years or older not on horm one therapy, who 
has had at least 12 months of spontaneous amenorrhea; or
iii. awom an 55 y ears or olderwith a diagnosis of menopause 
prior to starting hormone replacement therapy .
Informed Consent
[6] are reliable and willing to make themselves available for the duration of the 
study  and are willing to follow study  procedures;
[7] h ave given wri tten informe d consent approved by  Lilly and the inst itutional 
review board (IRB) governing the site.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 33
LY32981766.2. Exclusion Criteria
Subjects will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening:
Medical Conditions -General
[8] have a max imum body  circumference >219 cm (i.e., at the widest point of the 
body ) or a body  weight >22 5 kg, in order to not exceed the body  size 
limitations imposed by the MRI scanner machinery ;
[9] h ave a history  or current cardi ovascular (e.g., myocardial infarct ion, 
congest ive heart failure, cerebrovascular accident, venous thromboembolis m), 
respi ratory , hepat ic, renal, GI, endocrine, hematological (including history  of 
thrombocy topenia), or neurol ogical disorders capable of significant ly altering 
the absorpti on, metabolism, or eliminat ion of drugs; or constituting a risk 
when taking the IP; or may interfere with the interpretation of data;
[10] have obesit y induced by  other endocrinol ogic disorders (e.g., Cushing 
syndro me) or diagnosed monogenet ic or syndromic for ms of obesit y (e.g., 
melanocortin 4 receptor deficiency or Prader -Willi syndrome)
[11] h ave acute or chroni c pancreat itis or a history  of acute i diopathi c pancreat it is; 
or have other GI disorders (e.g., relevant esophageal reflux or gall bladder 
disease) that could be aggravated by  GLP -1 analogs; 
Subjects who have had cho lecysto lithiasis (removal o f gall stones) 
and/or cholecystectomy (removal of gall bladder) in the past, with no 
long-term com plicat ions, are eligible for participatio n;
[12] have a known clinically significant gastric empt ying abnormalit y (e.g., severe 
diabetic gastroparesis or gastri c outl et obstructi on)or chronically  take drugs 
that direct ly affect GI motilit y.
[13] haveor plan to have endoscopi c and/or device -based therapy  for obesi ty 
or have had device removal wit hin the last 6 months (for example, mucosal 
ablat ion, gastric artery  embo lization, intragastric balloon and duodenal- jejunal 
bypass sleeve)
[14] have a pri or or planned surgi cal treatm ent for obesi ty (excluding liposuct ion 
or abdominoplast y if performed >1 year prior to screening)
[15] h ave an estimated glomerular filtration rate (eGFR) <60mL/min/1.73 m2, 
calculated by Chronic Kidney Disease
-Epidemi ology atscreening.
[16] have an intention to enter into a weight loss program during the study;
[
17] have a personal or family history  of medullary  thyroi d carcino ma (MTC), 
have mult iple endocrine neoplasia syndro me type 2 (MEN 2), or calcitonin 
≥20pg/m L at scre ening;
[18] a re diagnosed with any form of diabetes prior to entry  or have a hemoglo bin 
A1c (HbA1c) value at screening of ≥6.5%;
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 34
LY3298176[19] h ave findings in the 12 -lead ECG at screening that, in the opinio n of the 
investigator, may increase the risks of potentia lly clinically relevant 
worsening associated with participat ion in the study;
[
20] h ave bl ood pressure of ≥160/90 mmHg and/or pulse rate of < 45or >100 bpm 
(supine) at screening wit h or without stable doses [at least 1month prior to 
screening] of ant i
-hypertensio n medications;
[21] h ave an act ive or un treated m alignancy or have been in remission fro m a 
clinically significant malignancy (other than basal or squamous cell skin 
cancer, in situ carcino mas of the cervix, or in situ prostate cancer) for <5 years
prior to screening;
[
22] h ave evidence of human immunodeficiency  virus (HIV) and/or posi tive HIV 
antibodies at screening;
[
23] h ave evidence of hepatit is B or posit ive hepat itis B surface ant igen and/or 
evidence of hepatit is C virus (HCV) or hepa titis C a ntibody
 at screening;
subjects wi th a previ ous di agnosis of HCV who have been treated with 
antiviral therapy  and achieved a sustained viro logical  response m ay be 
eligible for inclusio n in the study, provided they have no detectable 
HCV RNA on the screening HCV polymerase chain reaction test.  A 
sustained viro logical response i s defined as an undetectable HCV RNA 
level 24 weeks after complet ion of a full, documented course of an 
approved antiviral therapy  for HCV.
subjects who have spontaneously cleared HCV infection, defined as (1):  
a posi tive HCV antibody  test and (2):  a negat ive HCV RNA test, with 
no history  of anti-HCV treatment, may be eligible for inclusio n in the 
study , provi ded they  have no detectabl e HCV RNA on screening for this 
study .
[24] h ave s erum  aspartate aminotransferase (AST) or alanine aminotransferase 
(ALT) >
2.0× the upper limit of normal (ULN) ,total bilirubin (TBL) >1.5 ×
ULN (except for subjects with Gilbert’s syndro me, which can be enrolled with 
TBL <2.0 ×
ULN), or alkaline phosphatase (ALP) >1.5× ULN ; 
subjects wi th non-alcoho lic fatty liver disease are eligible for 
participat ion;
[25] h ave had a blood donation of 450 mL or more in the last 3 months or any  
blood donation wit hin the last month prior to scre ening;
[26] h ave a history  of drug or alcohol abuse within the last 12 m onths pri or to 
screening ;or a posi tive drug or alcoho l screen; and/or smoke >10 cigarettes 
per day  or the equivalent;
[27]have a history  of marijuana use within 3 months of enrollmen t and 
unwillingness to abstain fro m marijuana use during the trial.  Subjects should 
also refrain use o f cannabidio l oilfor the durati on of  the study .  
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 35
LY3298176[28] h ave had a blood transfusio n or severe blood loss within the last 3 months, or 
have a hemoglobin value <11 g/dL (males) or <10 g/dL (females), 
[
29] h ave an average weekly  alcohol  intake that exceeds 21 units per week (males) 
and 14 units per week (females) (1 unit = 12 oz or 360 mL of beer; 5 oz or 
150mL of wine; 1.5 oz or 45 mL of dist illed spirit s), and/or are unwilling to 
stop al coho l consumpt ion 12hours before each CRU outpati ent vi sit
;
[30] have any lifet ime history  of a sui cide attem pt ;
[31] Have a Patient Health Questionnaire -9 (PHQ -9) score of 15 or more at 
screening;
[32]On the Columbia -Suicide Severi ty Rating Scale (C -SSRS) at screening:
•a “yes” answer to either Quest ion 4 (Act ive Suicidal Ideat ion with Som e 
Intent to Act, Without Specific Plan) or
•a “yes” answer to Question 5 (Active Suicidal Ideation wit h Spe cific Pl an and 
Intent) on the “Suicidal Ideat ion” portion of the C -SSRS, or
•a “yes” answer to any  of the suicide -related behaviors (Actual Attempt, 
Interrupted Attempt, Aborted Attempt, Preparatory Act or Behavior) on the 
"Suicidal Behavior" porti on of  the C -
SSRS, and
•the ideation or behavior occurred within the past month
[33] h ave a history  of atopy  or clinically  significant m ultiple or severe drug 
allergies, or severe post -treatment hypersensit ivity reacti ons (including, but 
not limited to, ery thema mul tiforme major, linear immunogl obulin A 
derm atosis, toxic epidermal necrolysis, or exfo liative dermatit is).
Prior/Concomitant Therapy -General
[
34] have current or history  of (within 6months prior to screening or between 
screening and ran domizati on) treatm ent wi th medicati ons that m ay cause 
significant wei ght gain, including but not limited to:  tricyclic ant idepressants, 
atypical ant ipsychotic mood stabilizers for example:
Tofranil ®(imipramine ), 
Elavil®(amitript yline ), Rem eron ®(mirtaza pine), 
Paxil ®/Seroxat ®(paroxetine ), Nardil ®(phenelzine ), Largactil ®
(chlorpromazine ), Mellaril ®(thioridazine ), Clo zaril ®/FazaClo ®/Versacloz ®
(clozapine ), Zyprexa ®(olanzapine ), Depakote ®/Convulex ®(valproic acid )
and its derivat ives, and/or Lithobid ®(lithium )
Note :  select ive serotonin reuptake inhibitors other than paroxetine are 
permitted.
Use of o ther medicat ions not listed above, may resul t in subject exclusio n at 
the discret ion of the invest igator in consultat ion with the Sponsor .  
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 36
LY3298176[35] have take n within 6months pri or to screening or between screening and 
rando mizat ion, medicat ions (prescribed or over -the
-counter) or alternat ive 
remedies intended to promote weight loss.  Examples include, but are not 
limited to:
Saxenda ®(liraglutide 3.0 mg) , Xenical ®/Alli®(orlistat) , Meridia ®
(sibutramine) , Acutrium ®(phenylpropanolamine) , Sanorex ®(mazindo l), 
Adipex ®(phentermine) , BELVIQ ®(lorcaserin) , Qsymia ®
(phentermine/topiramate combinat ion), and/or Contrave ®
(naltrexone/bupropion) .
Note:  Use of met formin or any other glucose -lowering medication, whether 
prescribed for polycyst ic ovary syndro me or diabetes prevent ion is not 
permitted .  
Use of other medicat ions not listed above, may result in subject exclusio n at 
the discret ion of the invest igator in c onsul tation with the Sponsor.
[36] h ave received chronic (last ing >14 consecut ive days) systemic glucocortico id 
therapy  (excluding topi cal, intra -articular, and inhaled preparations) within 
1mont
h before screening, or between screening and randomizat ion;
[37] h ave been treated with any  glucose -lowering agent during the last 3 months 
prior to screening or between screening and randomizat ion;
[
38] have received treatment with a drug that has not received regulatory  approval  
for any  indicati on wi thin 3 mo nths or 5 half-lives (whichever is longer) of 
screening.
Prior/Concurrent Clinical Trial Experience
[
39] a re persons who have previously co mpleted or withdrawn fro m this study;
[
40] h ave known allergies to tirzepatide or GLP - 1RAs;
[41] h ave previ ous exposure to ti rzepat ide or exposure to GLP -1 RA in the 
previous 6 months prior to screening and between screening and 
rando mizat ion;
[
42] are currently  enrolled in a clinical study  involving an IP or any other type of 
medical research judged n ot to be sci entifically or medically co mpat ible with 
this study .
Other Exclusions
[43]female subjects who are breastfeeding;
[44]suffer from claustrophobia sufficient ly severe that it may preclude co mpletion 
of MRI scanning ;
[45]have contraindicat ions such as cardiac pacemakers, aneury sm clips ,or other 
metallic implants considered unsafe for MRI scanning ;
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 37
LY3298176[46] a re invest igative site personnel direct ly affiliated with this study  and thei r 
immediate families.  Immediate family is defined as a spouse, par ent, child, or 
sibling, whether bio logical or legally adopted;
[
47] a re Eli Lilly  and Com pany empl oyees;
[
48] a re deem ed unsui table by the invest igator for any other reason.
6.3. Lifestyle and Dietary Requirements
Throughout the study , 
subjects may undergo m edical assessments and review of compliance with 
requi rements before continuing in the study .
6.3.1. Meals and Dietary Restrictions
Subjects shall fast for at least 12hours overnight prior to each outpatient visit where fast ing 
samples are drawn .  Subj ects will fas t for at l east 12hours prior to tirzepat ide/placebo dosing, 
after whi ch subjects will receive a meal.  Liraglut ide will be dosed without regard to timing of 
meals .  Water can be consumed freely.  
Subjects will only consume lunch test meal provi ded by  theCRU during outpati ent visi ts.  
Further details regarding dietary  requi rement sfor the planned assessments in the CRU at 
baseline, Week 3 , and Week 6 of the treatm ent period, and 3 and 4 weeks post final dose of the 
follow-up period are described in Appendix 5 .  
6.3.2. Caffeine, Alcohol, and Tobacco 
Regular caffeine drinkers are required to maintain their usual amount of caffeine intake 
throughout the study  including on CRU outpatient vis it days .  
No al coho l will be allowed at least 12 hours before each CRU outpatient visit .  Between CRU 
outpati entvisits, weekly alcoho l shoul d not exceed 21 units per week for males and 14 units per 
week for females (a unit is defined in Section6.2Exclusio nCriteria).  
Subjects will not be allowed to use tobacco products in the CRU .
6.3.3. Activity
Subjects will be advised to maintain their regular levels o f physical act ivity/exercise during the 
study .  No intense physical act ivity will be all owed f or at l east 48 hours before each CRU 
outpati ent visi t.  When certain study  procedures are in progress at the CRU, subjects may  be 
requi red to rem ain recumbent or si tting.  
6.4. Screen Failures
Screening tests such as clinical laboratory  tests and vi tal signs/ECGs may  be repeated at the 
discreti on of  the invest igator .  Individuals who do not meet the criteri a for parti cipat ion in this 
study  (screen failure) may be re -screened up to 1 ti me.  The interval between re -screenings 
shoul d be at l east 2 weeks.  Each time re -screening is performed, the individual must sign a new 
ICF and will be assigned a new site screening number.  Subject numbers/enro llment numbers are 
assigned on the morning of Day 1.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 38
LY32981767.Treatment
7.1. Treatment Administ ered
Subjects will receive t irzepat ideor placebo administered SC QW for 6doses or liraglut ide 
administered SC QD for 38days.  Table GPHH .2shows the treatment regimens.
Table GPHH .2. Study Treatments and Dose Escalation
Dosing Schemes
Treatment Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
Tirzepatide 1 × 5 -mg PFS 
(Day  1)1 × 5 -mg PFS 
(Day  8)1 × 5 -mg PFS 
(Day  15)1 × 10 -mg 
PFS (Day 22)1 × 10 -mg 
PFS (Day 29)1 × 10 -mg 
PFS (Day 36)
Placebo 1 × PFS 
(Day  1)1 × PFS 
(Day  8)1 × PFS 
(Day  15)1 × PFS 
(Day  22)1 × PFS 
(Day  29)1 × PFS 
(Day  36)
Liraglutide 0.6 mg QD
(Day s 1-7)1.2 mg QD
(Day s 8-14)1.8 mg QD
(Day s 15-21)2.4 mg QD
(Day s 22-28)3 mg QD
(Day s 29-35)3 mg QD
(Day s 36-38)
Abbreviations:  PFS = prefilled syringe ; QD = once daily .
Tirzepati deor placebo will be administered QW at the CRU in a blinded fashio n.  
Liraglut ide will be administered QD in an open -label manner andwill be self -admin istered in the 
evening by the subject at home.   Subjects will receive adequate training for liraglut ide 
self-administrati on from site personnel .  
All injecti ons will be administered into the SC tissue of the abdominal wall.  Inject ion sites will 
be alternated weekly for tirzepat ide/placebo and daily for liragluti de,between 4 sites (right and 
left lower quadrants and ri ght and left upper quadrants) of the abdominal wall.
Dosing will occur at approximately the same time of day  in all groups and on the same day for 
the QW groups .  The actual time of dos ing will be recorded in the subject’s electronic case report 
form (eCRF).  
Whenever possible, IP administration at the CRU shoul d be carri ed out by  the sam e personnel.  
Addit ional details are provided in Secti on7.3(Blinding).  The personnel who administer study  
drugs will be unblinded to liraglut ide, but they will remain blinded to subjects receiving 
tirzepat ide or placebo .  
The investigator or designee is responsible for :
explaining the correct use of the IP to the site personnel 
verifying that instructions are fo llowed properly
maintaining accurate records of IP dispensing and collect ion
and returning all unused medicat ion to Lilly or its designee at the end of the study
Note : In some cases, sites may destroy  the m aterial  if, during the invest igative site select ion, the 
evaluator has verified and documented that the site has appropriate facilit ies and wri tten 
procedures to dispose of clini cal materials.  
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 39
LY3298176The site will be instructed to discard used medicat ions according to local regulat ions.
7.1.1. Packaging and Labeling
Tirzepati de and matching pl acebo will be supplied by  Lilly .  Tirzepat ide will be provided as 
prefilled syringes (PFS) containing 0.5 m L solution and provi ded in individual cartons to be 
dispensed.   Placebo will be provided as matching 0.5 -mL PFS .  
Liraglut ide will be the posit ive control and the commercially available formulat ion(Saxenda ®)
will also be supplied by  Lilly .
The IPwill be labeled according to the country’s regulatory  requi rements.
7.2. Method of Treatment Assignment
Subjects who meet all criteria for enrollment will be randomized in a 1:1 :1ratio to receive 
tirzepat ide, liraglutide, or placebo .  Assignment to treatment will be determined by a 
rando mizat ion table wit h treatment codes .  The randomizat ion will be stratified by  baseline BMI 
(27to <30 kg/m 2, 30 to <35 kg/m 2, and 35 to 50kg/m 2).  
7.2.1. Selection and Timing of Doses
The doses will be administered QW (tirzepat ideor placebo) or QD ( liraglut ide) according to the 
rando mizat ion schedule, on the same day o f the week (QW doses) and at approximately the same 
time of the day .  The actual t ime of all dose administrations will be recorded in the subject’s 
eCRF.
Tirzepati de and placebo will be administered in the morning of each dosing day  following an 
overnight fast of at least 12hours.  Liraglut ide will be administered in the evening of each dosing 
day without regard to timing of meals .  
A visit window (±1 day )maybe used for dosing of tirzepat ide or placebo only when the subjec t 
is unable to visit the CRU on the scheduled day.  If a subject is not able to receive his /her
tirzepat ide or placebo dose on the scheduled day (±1 day ), the dose shoul d be administered as 
soon as possible and at least 72 hours prior to the next scheduled dose.  If the remaining time to 
the next scheduled dose is less than 72 hours, the dose will not be administered and will be 
considered a missed dose.   
Invest igator site staff will take re asonable steps to educate and inform study  subjects randomized 
to liraglut ideto be com pliant to their treatment (e.g. ,written instructi ons, reminder calls, verbal 
reinforcement during clinic visits).  If a subject misses their daily dose of liraglut ide, the subject 
will be instructed to administer themissed dose as soon as they  remember , then administer the 
next daily  dose as usual on the fo llowing day .  The subject will be instructed not to administer an 
extra dose or increase their dose on the fo llowing day  to m ake up for the missed dose. If a 
subject misses their daily dose of liraglut ide for 2 days or more,they will be instructed to contact 
staff at the CRU .  
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 40
LY32981767.3. Blinding
The sponsor, i nvest igators ,and subjects will be blinded to tirzepat ideand pl acebo treatm ent 
assig nments ; however, liraglut ide will be administered in an open -label manner.  Therefore, the 
study  will be considered partially blinded.
Blinding between ti rzepati de and placebo will be maintained throughout the conduct of the study 
as described in the separate Blinding and Unblinding Plan .  To preserve the blinding of 
tirzepat ide and placebo allocat ion, all study  site personnel, except thosewho dispense and 
administer tirzepati de and placebo , will be blinded to treatm entallocat ion.  Ti rzepat ide, placebo, 
and liraglut idewill be dispensed by the site pharmacy  in accordance to the randomizat ion table.  
The site staff will take the necessary steps to ensure that subjects will remain blinded to 
tirzepat ide and placebo administration .  
If a subject’s study  treatm ent assignment is unblinded (tirzepat ide or placebo only) , the subject 
must be discont inued fro m the study , unless the investigator obtains specific approval fro m a 
Lilly clinical pharmaco logist ( CP)or clinical research physi cian ( CRP )for the subject to 
continue in the study .  During the study , emergency  unblinding shoul d occur only  by accessing 
the subject’s e mergency code.
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
ofa subject’s treatm ent assi gnment (tirzepat ide or placebo only) is warranted for medical 
management of the event. The subject’s safet y must al ways be the first considerat ion in making 
such a determination.  If the invest igator decides that unblinding is warranted, it is the 
responsibilit y of the invest igator to prompt ly document the decisio n and rationale and notify 
Lilly as soon as possible.
Upon com pletion of the study , all codes m ust be returned to Lilly  or its designee.
7.4. Dose Modification
The subject should fo llow the pl anned dosing regimen.  In the case of poor tolerabilit y during the 
study , dosing may need to be terminated following the gui dance provi ded in Section8.1.1
(Perm anent Di scontinuati on from Study  Treatm ent).
Deviat ionsfrom the planned tirzepat ide dose escalati on aregenerally not permitted ; however, at 
the discret ion of the invest igator, subjects may dose escalate to 10 mg tirzepati de 1 week later
than planned if expected to improve tolerabilit y. A delay  in dose escalat ion of tirzepat ide will 
not impact the planned total treatm ent durati on. Deviat ions from the planned li raglutide dose 
escalat ion are not permitted. 
7.4.1. Special Treatment Considerations
7.4.1.1. Management of Subjects with Gastrointestinal Symptoms
The ti rzepat ide and liraglut ide dose -escalation schemes have been designed to minimize the 
development of intolerable GI symp toms.  The dose -escalat ion peri od for tirzepat ide is 
considered to be 3 weeks to reach the 10 -mg dose.  The dose -escalat ion peri od for liraglut ide is 
considered to be 4 weeks to reach the 3 -mg maintenance dose.  During the dose -escalat ion 
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 41
LY3298176period, every  effort shoul d be m ade by  the investi gator to be able to escalate and maintain 
subjects on the corresponding study  drug dosage .  
To mit igate GI symptoms and manage subjects with poorly tolerated GI AEs, the invest igator 
shoul d:
Advise subjects to eat smaller meals, for example, splitt ing 3 daily  meals into 4 or m ore 
smaller meals, and to stop eating when they  feel full.
Prescribe symptomat ic med ication (f or example, ant i-emetic or anti -diarrheal  medicat ion) 
per local country  availabilit y and individual subject needs.
Discontinuati on from study  treatm ent as per gui dance provi ded in Secti on8.1.1
(Perm anent Di scontinuati on from Study  Treatm ent).
7.5. Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained , as communicated by s ponsor, during transit for all IPreceived and any discrepancies 
are reported and resolved be fore use of the study  treatm ent.
Only participants enro lled in the study  may receive IPor study materials, and only authorized 
site staff may supply or administer IPwhile in the CRU .Subjects will receive training from only 
authori zed si te staff on how to self -administer liraglut ideat hom e.  
All IPshoul d be stored i n anenvironmentally controlled and monitored (manual or automated) 
area in accordance with the labeled storage condit ions with access limited to the invest igator and 
authori zed si te staff .
The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  treatm ent accountabilit y, reconciliat ion, and record maintenance ( such as
recei pt, reconciliat ion,and final disposit ion records) .
7.6. Treatment Compliance
Tirzepati de and placebo will be administered at the study  site and docum entati on of  treatment 
administration will occur at the site.  Liraglutide will be self -administered at home and 
compliance will be assessed at each visit by  direct questi oningand subject diaries .  Deviati ons 
from the prescribed dosing regimen should be recorded in the e CRF .  
Subjects rando mized to receive liraglut idewho are repeatedly  (2 or m ore epi sodes) nonco mpliant 
with dosing will be reviewed by  the invest igator and sp onsor to determine if the subject should 
continue treatment or be discont inued fro m the study .
7.7. Concomitant Therapy
Secti on6.2(Excl usion Criteria) provi des a list of excluded medicat ions in this study  prior to 
rando mizat ion (e.g., weight -modifying agents, sy stemic glucocorti coids, glucose -lowering 
agents ).  These medicat ions are also not allowed during the treatment period.  
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 42
LY3298176Subjects on stable conco mitant m edicat ion at the time of study  entry , other than those that are 
prohibited, should continue their regular, unchanged dose throughout the study.  
In general, concomitant m edicat ion shoul d be avo ided; however, acetaminophen (1g, maximum 
3g/24 hours) may be administered at the discretion of the invest igator for treatment of headaches 
etc.  If the need for concomitant medicat ion (other than acetaminophen) arises, inclusi on or 
continuat ion of the subject may be at the discret ion of the invest igator after consultation wit h a 
Lilly CPorCRP .  
Any medicat ion used during the course of the study must be documented in source documents 
and entered into the eCRF.  
7.8. Treatment after the End of t he Study
Not applicable.  Tirzepat ide and liraglutide will not be made available to subjects after 
completion of the study .
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 43
LY32981768.Discontinuation Criteria
Subjects discont inuing fro m the treatm ent prem aturely  for any reason shoul d com plete an early 
termination visit and safet y follow-up visit procedures per Section 2(Schedule of Act ivities) of 
this protocol .
8.1. Discontinuation from Study Treatment
8.1.1. Permanent Discontinuation from Study Treatment
Possible reasons leading to permanent discontinuatio n of IP :
The subject requests to discontinue IP
If asubject i sinadverten tlyenrolledand it is determine dthatcontinued treatment with IP 
would not bemedically  appropri ate (Section 8.1.2 Discontinuati on of  Inadvertent ly 
Enrolled Subjects)
If a subject is diagnosed with acut e orchroni cpancrea titisafter randomizati on
If a subject i s confirmed to have developed T2DM after randomizati on
Ifa subject is diagnosed withMTC afterrando mization
If asubject i sdiagnose dwith an activ e oruntreated malignanc y(othe rthan basa l or
squamou scellskin cancer, in situ carcino mas of the cervix, or in situ prostat ecancer )
afterrandomiza tion
If the invest igator, after consultation with the sponsor -designated medical mo nitor, 
determines that a systemic hypersensit ivity react ion has occurred related to study  drug 
administration
If a subject is diagnosed wit h any other TEAE, SAE, or clinically  significant l aboratory
value for which the invest igator bel ieves that permanent IP discontinua t ion is the 
appropriate measure to be taken
Iffemalesubject becomes pregna nt
Discontinuati on of  the IP for abnormal liver tests should be considered by the invest igator when 
a subject m eets 1 of the fo llowing condi tions after consultation wit h the Lilly -designated m edical 
monitor:
ALT or AST > 8×ULN 
ALT or AST > 5×ULN sustained for more than 2 weeks
ALT or AST >3 ×ULN and(TBL >2
×ULN orinternat ional norm alized rati o>1.5)
ALT or AST >3 ×ULN , with theappearance of fatigue, nausea, vo miting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 44
LY3298176Subjects who discont inue IP early will be also discontinued fro m the study  after performing the 
early  terminat ion (ET)visit and safet y follow-up visit procedures, as specified in Secti on2
(Schedule ofActivities).
8.1.2. Discontinuation of Inadvertently Enrolled Subjects
If the sponsor or invest igator ident ifies a subject who did not meet enrollment criteria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  CP/CRP and the invest igator to 
determine if the subject may cont inue in the study .  If both agree i t is medically appropriate to 
continue, the invest igator must obtain documented approval fro m the Lilly CP/CRP to allow the 
inadvertent ly enro lled subject to contin ue in the study  with or wi thout continued treatment with 
IP.  
8.2. Discontinuation from the Study
In addit ion to the situations that result in IP discontinuat ion described in Section8.1.1
(Perm anent Di scontinuati on from Study  Treatm ent), subj ects will be di scontinued in the 
following circumstances:
Enrollment in any other clinical study  involving an invest igational product or enrollment 
in any other ty pe of medical research judged not to be scient ifically or medically 
compatible with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP)
Invest igator Decisio n
othe invest igator decides that the subject should be discontinued from the study
oif the subject, for any  reason, requi res treatment with another therapeutic agent 
that has been demo nstrated to be effect ive for treatment of the study  indicat ion, 
discontinuat ion from the study  occurs pri or to introducti on of  the new agent
Subject Decisio n
othe subject ,or legal representative ,requests to be withdrawn from the study .
8.3. Subjects Lost to Follow -up
A subject will be considered lost to follow-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site personnel are expected to make 
diligent attempts to contact subjects who fail to return for a scheduled visit or were otherwise 
unable to be fo llowed up by  the si te.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 45
LY32981769.Study Assessments and Procedures
Secti on2lists the Schedule of Act ivities, detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix 2 lists the laboratory tests that will be performed for thi s study .
Appendix 4 provi des a summary  of the m aximum  number and vol ume of invasive samples, for 
all sampling, during the study .
Appendix 5 details the procedures for efficacy assessments .  
The specificat ions in this protocol for the timings of safet y and sample co llections are given as 
targets to be achieved wit hin reasonable limits.  Modificat ions may be made to the time po ints 
based upon emerging clinical informat ion.  The scheduled t ime points may be subject to minor 
alterati ons; however, the actual time must be recorded correctly in the eCRF.  Failure or delays 
(i.e., outside st ipulated time allowances) in performing procedures or obtaining samples due to 
legitimate clinical issues (e .g., equi pment technical problems, venous access difficult y, or subject 
def
aulting or turning up late on an agreed scheduled procedure) will not be considered as 
protocol  deviations but the CRU will st ill be required to notify the sponsor in writ ing via a file 
note.
Unless otherwise stated in subsect ions below, all s amples collected for specified laboratory  tests 
will be destroy ed wi thin 60 days of receipt of confirmed test r esults.  Certain samples may be 
retained for a longer period, if necessary , to com ply with applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1. Efficacy Assessments
In thi s study , the m easures used to assess mechanisms of act ion of study  treatments with respect 
to energy intake, and central  reward and appetite circuits are considered efficacy measures.  The 
planned assessments will be performed at baseline , Week 3, and Week 6 .  Food intake tests will 
also be completed 3 and 4 weeks fo llowing the final  dose of study  drug in the fo llow-up peri od.  
All param eter calculat ions, when applicable, and analyses are described in Section10.3
(Statist ical Analyses ) orin the statistical analysis plan (SAP) .
9.1.1. Appetite and Eating Behavior Assessments
To characterize the treatment effect on energy intake, clinic -based food intake test will be 
completed at the time points specified in the Schedule of Act ivities (Secti on2).  Energy  intake 
(kcal ) will  be the primary endpoint .  
Thetreatm ent effect on attitude toward sfood will be assessed with the use of several  
food-related questionnaires ,completed at the time points specified in the Schedule of Act ivities 
(Secti on2).  The following quest ionnaires will be applied : 
appeti te visual analog scale (VAS) for hunger, fullness, sat iety, prospective food 
consumption, desire for specified foods, and overall appetite score 
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 46
LY3298176Food Crav ing Inventory (FCI)
Food Craving Q uesti onnai re-State (FC Q-S)
Eating Inventory
Power of Food Scale
A full descript ion of allappet ite and eating behavior assessment methods are detailed in 
Appendix 5 .  
9.1.2. Neuroi maging Assessments
To characterize the treatment effect on central reward and appeti tecircuits in the brain, fMRI 
scans will be co mpleted at the time po ints specified in the Schedule of Activit ies (Secti on2).  
BOLD fMRI: Day 
-4to Day  -1 (baseline), Day  16 (Week 3 , Visit 6), and Day  37 (Week 
6, Vi sit 11) 
On each day , BOLD f MRI scan will be completed in the fast ing state and subjects will perform a 
food image task during each scan .  
The principal brain reward areas to be examined will be the:
insula
medial frontal  gyrus
superi or tem poral  gyrus
precentral  gyrus
cingulate gyrus
In addit ion,exploratory  brain reward areas to be examined will be the
:
hippocam pus
putam en
orbitofrontal  cortex
ventral  striatum  
The change from baseline to Week 3 in BOLD fMRI brain activationin response to images of 
highly  palatable foods versus non -food obj ectsduring fasting state will be considered as a 
secondary  endpoint in the current study .  All other data collected fro m functional neuroimaging 
will be considered exploratory .  
A full descript ion of the MRI assessment method , including the food image task, is detailed in 
Appendix 5 .  
Impulsivit y assessments are described in Appendix 5 .
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 47
LY32981769.1.3. Hormone and Metabolite Assessments
To explore potential effects of study  treatm ent on horm ones and m etabo litesrelated to appetite 
and the regul ation of nutrient metabo lism, p lasma or serum samples wi ll be collected at the time 
points provided in the Schedule of Act ivities (Section 2).  
The changes fro m baseline to Week 3 and Week 6 of the following horm ones and metabo lites
will be considered exploratory  endpoints :
amylin
ghrelin
GIP
GLP -
1
leptin
pancreat ic po lypept ide
pepti de YY
insulin
glucagon
In addit ionto safet y monitoring , fasting plasma glucose and triglycerides will be measured as 
efficacy  endpoints at 
baseline, Week 3 and Week 6 .  
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of subjects who have entered this study  
and for al erting Lilly  or its de signee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the subject.
The invest igator is responsible for the appropriate medical care of subjects during the study.
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the invest igational 
product or the study , or that ca used the subject to discontinue the invest igational product before 
completing the study.  The subject should be fo llowed unt il the event resolves, stabilizes with 
appropriate diagnostic evaluation, or is reasonably explained.  The frequency o f follow-up 
evaluat ions of the AE is left to the discret ion of the invest igator.
The invest igator will record all relevant AE and SAE informat ion in the eCRF .  After the ICF is 
signed, s tudy site personnel  will record ,via eCRF ,the occurrence and nature of each subject’s 
preexist ing condit ions.  Addit ionally, site personnel  will record any  change in the condit ion(s) 
and the occurrence and nature of any AEs.  
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 48
LY3298176The invest igator will interpret and document whether or not anAE has a reasonab lepossib ility 
of being related to study treatment , or a study procedure, concomitant treatment or pathologies.  
A “reasonable possibilit y”means that there is a potenti al cause and effect relat ionship between 
the invest igational product, study  device and/or study  procedure and the AE.
Planned surgeries should not be reported as AEs unless the underlying medical condit ion has 
worsened during the course of the study .
If a subject’s IP is discont inued as a result of an AE, study  site personnel  mustreport thi s to Lilly 
or its desi gnee via eCRF.
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing:
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience (that is, immediate risk of dyi ng)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospitalization but m ay jeopardi zethe pati ent or may  requi re intervent ion to prevent 
one of the other outcomes listed in the definit ion above
when a condit ion related to the PFS necessitates medical or surgical intervention to 
precl ude ei ther perm anent impairment of a body  function or per manent damage to a body  
structure, the seri ous outcom e of “requi red intervent ion” will be assigned.
Study  site personnel  must al ert the Lilly  CP/CRP , or its desi gnee, of  any SAE as soon as 
pract ically possible.
Addit ionally , study site personnel  must al ertLilly Global Patient Safet y,or its desi gnee ,of any 
SAE wi thin 24 hours of invest igator awareness of the event via a sponsor -approved method.  If 
alerts are issued via telephone, they  are to be immedi ately fo llowed wi th official notification on 
study -specific SAE forms.  This 24 -hour notificat ion requirement refers to the init ial SAE 
inform ation and all fo llow-up SAE information.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued from and/or com pleted the study  (the subject summary eCRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study treatment or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .  
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 49
LY3298176Pregnancy (maternal or paternal exposure to IP) does not meet the definit ion of an AE.  
However, to fulfill regulatory  requi rements any  pregnancy  should be reported followi ng the SAE 
process to collect data on the outcome for both mother and fetus.
9.2.1.1. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator reports as related to IPor procedure.  Lilly  has procedures that 
will be fo llowed f or the recording and expedited reporting of SUSARs that are consistent with 
global regulat ions and the associated detailed guidance.
9.2.2. Adverse Events of Special Interest
9.2.2.1. Hypoglycemia
Tirzepati de is an incretin which acts on the pancreatic β cell as a non -secretagogue ;therefore, the 
risk of hypoglycemia is very low.  Similarly, the risk of hypoglycemia is considered low with 
liraglutide.  
If hypoglycemia occurs, each episode should be treated according to the standards of care by the 
investigator and addit ional monitoring of glucose levels may be requested at the invest igator’s 
discreti on. As a genera l safety precaut ion, subjects will be trained during the lead-in period
about si gns and symptom s of hypoglycemia ,how to treat hy poglycemia , and how to collect 
appropriate informat ion for each episode of hypoglycemia .
Hypoglycemia may  be identified by spontaneous reporting of symptoms from part icipants
(whether confirmed or unconfirmed by simultaneous glucose values) or by  blood gl ucose 
samples co llected during study visits.
Subject s may, at the investi gator’s di scret ion, be given gluco meters to assist in the evaluat ion of 
reported symptoms consistent with hypoglycemia .  Subjects receiving gluco meters will record 
relevant informat ion (for example, glucose values, symptoms) in a diary .
Invest igators should use the fo llowing definit ions and criteria when d iagnosing and categorizing 
an episode considered to be related to hy poglycemia (the PG values in this sect ion refer to values 
determined by a laboratory  or Internati onal Federati on of  Clinical  Chemistry  and Laboratory  
Medicine plasma -equivalent glucose met ers and strips) (American Diabetes Associat ion 2019):
Glucose Alert Value (Level 1):
Documented symptomatic hypoglycemia is defined as any time a subject feels
that he or she is experiencing symptoms and/or signs associated with 
hypoglycemia, and has a PG level of ≤70 mg/dL (≤3.9 mmo l/L)
Documented asymptomatic hypoglycemia is defined as any event not 
accompanied by t ypical symptoms of hypoglycemia, but with a m easured PG 
≤70mg/dL ( ≤3.9 mmo l/L)
Documented unspecified hypoglycemia is defined as any event with no 
inform ation about symptoms of hypoglycemia available, but with a measured PG 
≤70 m g/dL (≤3.9 mmo l/L)
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 50
LY3298176Clinically Significant Hypoglycemia (Level 2):
Docum ented symptomatic hypoglycemia is defined as any time a subject feels 
that he/she is experiencing symptoms and/or signs associated with hypoglycemia, 
and has a PG level of <54 m g/dL (<3.0 mmo l/L)
Documented asymptomatic hypoglycemia is defined as any event not 
accompanied by t ypical symptoms of hypoglycemia, but with a measured PG 
<54mg/dL (<3.0 mmo l/L)
Documented unspecified hypoglycemia is defined as any  event wi th no 
inform ation about symptoms of hypoglycemia available, but with a measured PG 
<54 m g/dL (<3.0 mmo l/L)
Severe Hypoglycemia (Level 3):
Severe hypoglycemia is defined as an episode with severe cognit ive impairment 
requi ring the assistance of another person to actively  administer carbohydrate, 
glucagon, or other resuscitative act ions.  These episodes may  be associ ated wi th 
sufficient neuroglycopenia to induce seizure or coma.  Blood glucose 
measurements may  not be available during such an event, but neurological 
recovery  attributable to the restoration of blood glucose to norm al is considered 
sufficient evidence that the event was induced by a low blood glucose
concentration.  
Other Hypoglycemia Categories:
Nocturnal hypoglycemia is defined as any hypoglycemic event that oc curs 
between bedt ime and waking
If a hypoglycemic event meets the criteria of severe, the invest igator must record the event as 
serious on t he AE eCRF and report itto Lilly  as an SAE.
To avoid duplicate reporting, all consecutive blood glucose values ≤70 mg/dL (3.9 mmol/L) 
occurring within a 1 -hour period may be considered to be a single hypoglycemic event (Weinberg 
et al. 2010; Danne et al. 2013).
In each case of suspected or confirmed hypoglycemia, it is important that the event be properly 
categori zed, the effect of the intervention be assessed, and the frequency of hypoglycemia be 
evaluated.  The role of dietary  changes and physica l exercise (or any  other contribut ing factor) in 
the development of an event should be established.  The subject should receive addit ional 
education, if deemed appropriate.
9.2.2.2. Pancreatitis
Glucagon -like peptide -1 receptor agonists have been associated with a possible risk of acute 
pancreat itis.  Acute pancreat itis is defined as an AE of interest in all studies with tirzepat ide 
including this study .  Acute pancreat itis is an acute inflammatory  process of the pancreas that 
may a lso invo lve peripancreat ic tissues and/or remote organ systems (Banks and Freeman 2006).  
The di agnosis of acute pancreat itis requires 2 of the fo llowing 3 features:
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 51
LY3298176abdo minal pain, characterist ic of acute pancreat itis (generally located in the 
epigastri umand radi ates to the back in approximately half the cases [Banks and 
Freeman 2006; Ko izumi et al . 2006]; the pain is often assoc iated with nausea 
andvomiting)
serum  amylase (total and/or pancreatic) and/or lipase ≥3×ULN
characterist ic findings of acute pancreat itis on computed tomography  (CT) scan or 
MRI
If acute pancreat itis is suspected, appropriate laboratory  tests (including levels of pancreat ic 
amylase and lipase) should be obtained via the local laboratory .  Imaging studi es, such as 
abdo minal CT sca n with or wi thout contrast, MRI, or gallbladder ultrasound, should be 
perform ed.  If laboratory  values and/or abdominal imaging support the diagnosis of acute 
pancreat itis, the subject must discont inue IP, and will be discont inued fro m the study  after 
completing all ET and fo llow-up procedures.  A review of the subject’s medical data, including 
concomitant medicat ions, should be conducted to assess potential causes o f pancreat itis.
Each case o f AE of pancreat itis must be reported.  If t ypical signs and/or s ymptoms o f 
pancreat itis are present and confirmed by laboratory values (lipase or amylase [total and/or 
pancreat ic]) and imaging studies, the event must be reported as an SAE.  For a potential case that 
does not m eet all of these criteria, it is up to the investigator to determine the seriousness of the 
case (AE or SAE) and the relatedness o f the event to IP.
Each subject will have measurements of amylase and lipase, which are part of the safet y 
laboratory  tests as shown in Section2(Schedule of Act ivities)to assess the effects of study  
treatm ent on pancreat ic enzyme levels.  Serial measures of pancreat ic enzymes have limited 
clinical value for predict ing episodes of acute pancreatit is in asymptomat ic subject s (Nauck et al. 
2017; Steinberg et al. 2017a; Stei nberg et al. 2017b).  Thus, further diagnostic fo llow-up of  cases 
of asymptom atic pancreat ic hyperenzymemia (lipase and/or pancreat ic amylase ≥3×ULN) is not 
mandated but may be performed based on the investigator’s clinical judgment and assessment of 
the subject ’s overall clinical condit ion.  If further diagnostic assessment due to asymptomat ic 
hyperenzymemia iswarranted, it should fo llow Lilly  standard al gorithm for the m onitoring of 
pancreat ic enzymes ( Appendix 7 ).
9.2.2.3. Thyroid Malignancies and C -Cell Hyperplasia
Individuals with personal or family history  of MTC and/or MEN 2 will be excluded from the 
study , as well  as those wi th calcitonin ≥20 pg/m L at screening. Participants who are diagnosed 
with MTC and/or MEN -2 during the study  will have study  drug stopped and should continue 
follow-up wi th an endocrino logist.
The assessm ent of  thyroid saf ety during the study  will include reporting of any  case of  thyroid 
malignancy ,including MTC and papillary carcinoma ,and measurements of calcitonin at 
screening .  This data will be captured in the specific section of the eCRFs.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 52
LY32981769.2.2.4. Hypersens itivity Events
Many  drugs, but parti cularly biologic agents ,carry the ri sk of systemic hypersensit ivity 
reacti ons. If such a react ion occurs, a dditional data describing each symptom should be provide d
to the sponsor in t he eCRF . 
The s ites shoul d have appropri ately  trained medical  staff  and appropri ate medical equipment 
available when study  parti cipants are receiving study  drug .It is recommended that participants
who experience a systemic hypersensit ivityreact ion be t reated per the local standard of care .  
In the case of generalized urticaria oranaphylaxis ,additional blood samples shoul d be co llected 
as described in Appendix 8 (Reco mmended Laboratory  Testing for Hy persensit ivity Events).  
Laboratory  resul ts are provi ded to the sponsor via the central laboratory .  
IP should be temporarily  interrupted in any  individu al suspected of having a severe or serious 
allergic reaction to IP.  IP may be restarted when/if it is safe to do so, in the opinio n of the 
investigator.  If IP is permanent ly discont inued, the subject will be discont inued fro m the study  
(Secti on8.1.1 Perm anent Di scont inuat ion from Study  Treatm ent).
9.2.2.5. Injection- Site Reactions
Inject ion-site assessments for l ocal tolerabilit y will be conducted, when reported as:
an AE fro m a subject, or
a clinical observat ion from an invest igator.
Reported inject ion-site reacti ons will  be characterized wi thin the fo llowing categori es:
edem a
erythema
induration
itching
pain
Inject ion-site reacti ons will  be collected on the eCRF created for these events.  At the time of AE 
occurrence, unscheduled samples may be collected for measurement of tirzepat ide ADA and 
tirzepat ide concentration if the event is suspected to be immune related by the investi gator.
All injecti on-site reacti ons reported as AEs will be closely monitored until reso lution.  The report 
of a clinically  significant AE of inject ion-site reacti on may prom pt notificati on of  the sponsor, 
clinical photography , and referral  for dermatologic evaluat ion and consideration of a skin biopsy 
and laboratory  evaluat ions (ALT, AST, complete blood coun t with percent eosinophils, and 
additional immunogenici ty testing).
Site staff will be provided wit h separate instructions/training on how t o eval uate inject ion-site 
reacti ons and thei r severi ty in a consistent manner.  Photographs of inject ion-site reacti ons m ay 
be taken in a standardized manner for record -keeping purposes; however, the photographs will 
not be used to evaluate the severit y ofinject ion-site reacti on.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 53
LY32981769.2.2.6. Hepatobiliary Disorders
All events of treatm ent-emergent biliary co lic, cholecyst itis, or other suspected events related to 
gallbladder disease should be evaluated and addit ional diagnostic tests performed, as needed.   In 
cases o f elevated liver m arkers, hepatic m onitoring shoul d be ini tiated as outlined in 
Secti on9.4.7.1 (Hepatic Safet y) and Appendix 6 (Hepati c Moni toring Tests for 
Treatment -Emergent Abnorm ality.
9.2.2.7. Severe Gastrointestinal Adverse Events
Tirzepati de or liraglut ide may cause severe GI AEs, such as nausea, vo miting, and diarrhea.  
Inform ation about severe GI AEs as well as ant iemetic/ant idiarrheal use will be collected in the 
AE form of the eCRF.  For detailed information concerning the man agement of GI AEs, refer to 
Secti on7.4.1.1 (Management of Subjects with Gastrointest inal Symptoms).
9.2.2.8. Acute Renal Events
Renal safety  will be assessed based on l aboratory  renal functional assessment as well as 
assessment of AEs suggest ive o f acute renal failure or worsening of chronic renal failure.  
Subjects with GI AEs, including nausea, diarrhea, and vo miting are at increased risk of 
developing dehydration.  Dehydrat ion may cause a deterioration in renal funct ion, including 
acute renal failure.  Subjects should be advised to notify invest igators in case of severe nausea, 
frequent vomit ing, or symptoms of dehydrat ion.
9.2.3. Complaint Handling
Lilly co llects product complaints on IPsand drug delivery  systems used in clinical trials in order 
to ensure the safet y of study  partici pants, m onitor quali ty, and to facilitate process and product 
improvements.
Subjects should be instructed to contact the invest igator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product or drug delivery system so that the 
situation can be assessed.
9.3. Treatment of Overdose
For the purposes of this study , an overdose of tirzepati de or li raglut ideis considered any dose 
higher than the dose assigned through randomizat ion.
For pati ents wi th suspected or confirmed overdose with tirzepat ide or liraglut ide, there is no 
specific ant idote.  The patient shoul d be watched for GI symptoms and hypoglycemia.  
Treatment is supportive, depending on the subject’s symptoms.   For detailed informat ion, refer to 
the IB for tirzepat ide and package insert for liraglutide .  
9.4. Safety
9.4.1. Laboratory Tests
For each subject, laboratory  tests detailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Act ivities (Secti on2).  
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 54
LY3298176With the exception o f safety laboratory  test resul ts that may  unblind the study , Lilly or i ts 
designee will provide the invest igator with the results of laboratory tests analyzed by a central 
vendor, if a central vendor is used for the study .
9.4.2. Vital Signs
Vital sign m easurements shoul d be taken before obtaining an ECG tracing, at visits where 
requi red (see Secti on 2, Schedule of Activit ies), and before collect ion of blood samples for 
labora tory testing. For each param eter, 2 m easurements will be taken using the same arm. An 
appropriately  sized cuff (cuff bladder encircling at least 80% of the arm) should be u sed to 
ensure the accuracy  of
 blood pressure measurements.   The arm  used for the b lood pressure
measurement should be supported at theheart level. The recordings should be taken at least 1 
minute apart. Each measur ement of si tting heart rate and blood pressure needs to be recorded in 
the eCRF. Any AE rel ated to changes in blood press ure and heart rate should be reported, per 
requi rements provi ded in Section 9.2.
Unscheduled orthostatic vital signs should be assessed, if possible, during any  AE of dizziness or 
posture -induced symptoms.  Addit ional vital signs may be m easured during each study  period if 
warranted.
9.4.3. Body Weight and Waist Circumference
Weight and waist circumference will be measured according to the schedule p rovided in the 
Schedule of Act ivities (Secti on2).  
Subjects will be weighed at approximately the same time in the morning, before dosing and after
an overnight fast and evacuat ion of the bowel and bladder, if possible. W
eight will be measured 
twice on each scheduled occasio n, wi th the subject stepping off the scale between measurements.  
A thi rd measurement will be made if the first 2 measurements are >0.5 kg apart. The 2 closest 
measurements will be recorded. Wherever possible, the same scale will be used for all weight
measurements throughout the study , and the scale will not be moved or recalibrated .Subjects 
will be weighed in light clothing .  Weight m easurements will be recorded in the source document 
and the eCRF .
Waist circumference will be measured at the midpoint between the inferi or border of the rib cage 
and the superior aspect of the iliac crest .  The s ubject will stand in a straight, upright posi tion 
with feet together and arms at theside. The area measured will be cleared of all clothing other 
than undergarments. The measurement should be taken at the end of normal expirat ion. Two 
separate measures will be taken and steps are rep eated until 2 measurements are obtained within 
0.5cm of each other.
9.4.4. Electrocardiograms
For each subject, single 12 -lead ECGs shoul d be collected according to the Schedule of 
Activities (Secti on2).  
Electrocardiograms must be recorded before collecting any blood s amples.  
Subjects must be 
supine for approximately  5 to 10 minutes before ECG collect ion and rem ain supine but awake 
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 55
LY3298176during ECG collect ion.  Electrocardi ograms m ay be obtained at addit ional times,when deemed 
clinically necessary .  All ECGs recorded should be stored at the invest igational site.
Electrocardiograms will be interpreted by  a qualified physician ( the investigator or qualified 
design ee) at the si te as soon after the time of ECG collect ion as possible, and ideally while the 
subject is st ill present, to determine whether the subject meets entry criteria at the relevant 
visit(s) and for immediate subject management, should any clinically relevant findings be 
ident ified.  
If a clinically significant finding is ident ified (including, but not limited to ,changes in QT/QTc 
interval  from baseline) after enrollment, the investigator will determine if the subject can 
continue in the study .  The invest igator ,or qualified designee ,is responsible for determining if 
any change in subject management is needed and must document his/her review of the ECG 
printed at the time of co llection.  Any clinically significant finding s from ECGs that resul t in a 
diagnosis and that occur after the subject receives first dose of the IP shoul d be reported to Lilly, 
or its desi gnee, as an AE via eCRF .
9.4.5. Physical Examinations
Physical examinat ions and routine medical assessments will be conducted as specified in the 
Schedule of Act ivities(Secti on2) and as clinically indicated.
9.4.6. Suicidal Ideation Assessment
Overweight and obese patients are at an increased risk of depressi on (Luppino et al . 2010).  
Depressio n can increase the risk of suicidal ideat ion and behavior.  Therefore, study  subjects will 
be screened at trial entry  for depressi on, suicidal  ideati on and behavi or using the C -SSRS and 
PHQ -9 as specified in the Schedule o f Activities (Secti on2).Subjects of higher risk of severe 
depressio n and/ or suicidalit y will  be excluded (refer to EC 28 -30, Section 6.2)
The C
-SSRS (Columbia Lighthouse Project [WWW]) is a scale that captures the occurrence, 
severit y, and frequency  of suicidal ideation a nd/or behavior during the assessment period.  The 
scale includes suggested questions to solicit the type of informat ion needed to determine if 
suicidal ideation and/or behavior occurred.  The tool was developed by  the Nat ional Inst itute of 
Mental Heal th trial group for the purpose of being a counterpart to the Columbia Classification 
Algori thm of Suicide Assessment categorizat ion of sui cidal  events.  For this study , the C -SSRS 
is adapted for the assessment of the ideat ion and behavior categories only.  The Intensit y of 
Ideati on and Lethalit y of Behavi or secti ons are rem oved
The PHQ -9 is a validated self -report screening tool that assesses the presence and intensit y of 
depressive symptoms.  The PHQ- 9, which incorporates the 9 Diagnostic and Statist ical Manual -
IV depression criteria as “0” (not at all) to “3” (nearly  every day ), was devel oped f or use in 
primary  care settings (Kroenke et al. 2001).
9.4.7. Safety Monitoring
The Lilly CPor CRP /scientist will mo nitor safet y data throughout the course of the study .
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 56
LY3298176Lilly will review SAEs wit hin time frames mandated by co mpany procedures.  The Lilly CPor 
CRP will periodically review the following data:
trends in safety  data
laboratory  analy tes including glucose, amylase, and lipase
serious and nonserious AEs, including AE s of interest ( see Section 9.2.2 )
When appropriate, the Lilly CPor CRP will consult with the funct ionally  independent Gl obal 
Patient Safet y therapeutic area physician or clinical research scient ist.
9.4.7.1. Hepatic Safety
Close hep atic monitoring
Laboratory  tests ( Appendix 6 ), including ALT, AST, ALP, TBL ,direct bilirubin , 
gamma- glutamyl  transferase ( GGT ), and creatine kinase (CK), shoul d be repeated wi thin 48 to 
72 hours to confirm the abnormalit y and to determine if it is increasing or decreasing, if 1or 
more of these condit ions occur:
If a participant with baseline results of ... develops the following elevations:
ALT or AST <1.5 ×upper limit of normal (ULN ) ALT or AST ≥3×ULN
ALP <1.5 ×ULN ALP ≥2×ULN
TBL <1.5× ULN TBL ≥2×ULN (except for patients with Gilbert’s syndrome)
ALT or AST ≥1.5×ULN ALT or AST ≥2×baseline
ALP ≥1.5×ULN ALP ≥2×baseline
TBL ≥1.5×ULNTBL ≥1.5×baseline (except for patients with Gilbert’s 
syndrome)
If the abnormalit y persists or worsens, clinical and laboratory  monitoring, and evaluat ion for 
possible causes of abnormal liver tests should be init iated by  the invest igator in consultat ion with 
the Lilly -designated CP/CRP .  At a minimum, this evaluat ion shoul d include physical 
examinat ion and a thorough medical history , including symptom s, recent illnesses (for example, 
heart failure, systemic infect ion, hypotension, or seizures), recent travel, history  of concomi tant 
medicat ions (including over -the-count er), herbal and dietary supplements, history  of alcoho l 
drinking and other substance abuse.
Initially, m onitoring of  symptoms and hepat ic biochemical tests should be done at a frequency o f 
1 to 3 times weekly , based on the parti cipant’s clinical condit ion and hepat ic biochemical tests .  
Subsequently, the frequency  of monitoring m ay be l owered to once every  1 to 2 weeks, if the 
participant’s clinical condit ion and l ab resul ts stabilize .  Moni toring of ALT, AST, ALP, and 
TBL should cont inue unt il levels norma lize or return to approximate baseline levels.
Com prehensive hepatic evaluation  
A co mprehensive evaluat ion shoul d be perform ed to search for possible causes of liver injury  if 
one or m ore of these condit ions occur:
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 57
LY3298176If a participant with baseline results of...  develops the following elevations:
ALT or AST <1.5 ×ULN ALT or AST ≥3×ULN with hepatic signs/symptoms*, or
ALT or AST ≥5×ULN
ALP <1.5 ×ULN ALP ≥3×ULN
TBL <1.5× ULN TBL ≥2×ULN (except for patients with Gilbert’s syndrome)
ALT or AST ≥1.5×ULN ALT or AST ≥2×baseline with hepatic signs/symptoms*, or
ALT or AST ≥3×baseline
ALP ≥1.5×ULN ALP ≥2×baseline
TBL ≥1.5×ULN TBL ≥1.5×baseline (except for patients with Gilbert’s syndrome) 
* Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, and/or 
eosinophilia >5%.
At a minimum, this evaluat ion should include physical examinat ion and a thorough medical 
history , as outlined above, as well as tests for prothrombin t ime-internat ional normalized rat io 
(PT-INR); tests for viral hepat itis A, B, C, or E; tests for autoimmune hepat itis; and an 
abdo minal imaging study (for example, ultrasound or CT scan).  
Based on the patient’s history  and initial resul ts, further testing should be considered in 
consultation wit h the Lilly -designated m edical m onitor, including tests for hepatit is D virus 
(HDV), cy tomegalovirus (CMV), Epstein -Barr vi rus (EBV), acetaminophen levels, 
acetaminophen protein add ucts, uri ne toxi cology screen, Wilso n’s disease, blood alcoho l levels, 
urinary  ethyl  glucuronide, and blood phosphat idylethano l. Based on the circumstances and the 
investigator’s assessment of the participant’s clinical condit ion, the investigator should consider 
referring the participant for a hepatologist or gastroenterologist consultation, magnet ic resonance 
cholangiopancreatography  (MRCP), endoscopi c retrograde cholangiopancreatography  (ERCP), 
cardi ac echocardi ogram , or a liver biopsy.  
Addit ional safety data collect ion in hepat ic safet y eCRF shoul d be perform ed in study  
participants who meet 1 or more of the fo llowing condi tions: 
Elevat ion of serum ALT to ≥5× ULN on 2or more consecutive blood tests (if baseline 
ALT <1.5× ULN)
oIn parti cipants wi th baseline ALT ≥1.5× ULN, the thresho ld is ALT ≥3×baseline 
on 2 or more consecutive tests
Elevated serum TBL to ≥2× ULN (except for cases of known Gilbert’s syndro me)
oIn parti cipants wi th baseline TBL ≥1.5× ULN, the thresho ld should be TBL ≥2×
baseline
Elevat ion of serum ALP to ≥2× ULN on 2 or more consecutive blood tests 
oIn parti cipants wi th baseline ALP ≥1.5× ULN, the thresho ld is ALP ≥2×baseline 
on 2 or more consecutive blood tests
Hepati c event consi dered to be a SAE
Discontinuati on of  study  drug due to a hepatic event.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 58
LY3298176Note: the interval between the 2 consecutive blood tests should be at least 2 day s.
9.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities, venous blood samples o f 
approximately  3mL each will be co llected to determine the plasma concentrations of tirzepat ide.  
A maximum of 3samples m ay be collected at additional t ime po ints during the study  if 
warranted and agreed upon between both the investigator and sponsor.  Instructions for the 
collect ion and handling of blood sam ples will  be provi ded by the sponsor .  The actual date and 
24-hour clock time o f each sampling will be recorded.
Drug concentration informat ion that m ay unblind the study  will not be reported to invest igat
ive 
site or blinded personnel unt il the study  has been unblinded.
9.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facilit y 
designated by  the sponsor .
Concentrations of tirzepat idewill be assayed using a validated liquid chro matography  mass 
spectrom etrymethod.  Analyses of samples collected fro m placebo -treated subjects are not 
planned.
Bioanaly tical samples collected to m easure IP concentrations will be retained for a maximum o f 
1 year fo llowing last subject visit for the study .  During thi s time, samples rem aining after the 
bioanalyses may  be used for expl oratory  analyses such as metabo lism work, protein binding, 
and/or bioanalyt ical method cross -validat ion.
9.6. Pharmacodynamic s
Briefly, PD assessments will include parameters of food intake, and centra l reward and appet ite 
circuits.  Adetailed descript ion of PD efficacy measures is provided in Section9.1(Efficacy 
Assessments).  A description o f procedures for obtaining the PD parameters is detailed in 
Appendix 5 and the analyses of these parameters is detailed in the SAP.
9.6.1. Immunogenicity Assessments 
At the visit s and t imes specified in the Schedule of Act ivities (Secti on2), venous blood samples 
will be co llected to determine ant ibody producti on against tirzepat ide.  
To interpret the results of 
immunogenicit y, avenous blood sample will be collected at the same time points to determine 
the plasma concentrati ons of tirzepat ide.
Immunogenicit y will be assessed by  a validated assay  designed to detect ADA s in the presence 
of tirzepat ideat a l aboratory  approved by the sponsor.  Antibodies may  be further characteri zed 
and/or evaluated for their abilit y to neutralize the activit y of tirzepat ide on GIP and GLP -1 
receptors.  Posit ive tirzepa tide ADA samples m ay also be tested for cross -reactivit y against 
native GIP and GLP -1, and, if posit ive, may then be tested for neutralizing ant ibodies against 
native GIP and/or GLP -1.  
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 59
LY3298176All subjects will have an ADA sample measured at ET and at the safet yfollow-up visi t.  A 
risk-based approach will be used to monitor subjects who develop TE- ADA, defined in 
Secti on10.3.4 (Evaluat ion of Immunogenicit y).
Every  attem pt shoul d be made to contact subjects for the fo llow-up immunogenicit y assessment; 
however, if subjects are unwilling or unable to return for the visit, this is not considered a 
protocol  violation.
Samples will  be retained for a m aximum  of 15 years after the last subject visit, or for a shorter 
period if local  regulat ions and IRBs allo w,at a facilit y selected by  the sponsor.  The durati on 
allows the sponsor to respond to future regulatory  requests rel ated to tirzepat ide.  Any  samples 
remaining after 15 y ears will be destroy ed.  
9.7. Genetics
A blood sample will be collected for pharmacogenetic analysis as specified in the Schedule of 
Activities, where l ocal regulati ons all ow.  
Samples willnotbeused to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variable exposure or response to 
tirzepat ide and to i nvest igate genet ic variants thought to play a role in T2DM , obesi ty, and/or 
diabetic co mplications.  Assessment of variable response may include evaluat ion of AEs or 
differences in efficacy.  
All samples will be coded with the subjec tnumber.  These samples and any  data generated can 
be linked back to the subject only by the inves tigativesite personnel .  
Samples will  be retained for a m aximum  of 15 y ears after the last subject visit, or for a shorter 
period if local regulat ionsand/or IRBs impose shorter time limits , for the study  at a f acilit y 
selected by Lilly or i ts desi gnee . This retention period enables use of new techno logies, response 
to regulatory  quest ions, and invest igation of variable response that may  not be observed unt il 
later in the devel opment of tirzepat ideor after tirzepati deis co mmercially available.  
Molecular techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named.  However, e xisting approaches include who le geno me or exome 
sequencing, geno me wide association studies, multiplex assays, and cand idate gene studies.  
Regardless of techno logy utilized, data generated will be used only  for the specific research 
scope described in this sect ion.  
9.8. Biomarker s
Biomarker research is performed to address questions of relevance to drug di sposi tion, target 
engagement, pharmacodynamics, mechanism o f action, variabilit y of subject response (including 
safet y), and clinical outcome.  Sample collect ion is incorporated into clinical studies to enable 
examinat ion of these questions through measurement of bio molecul es including DNA, RNA, 
proteins, lipids, and other cellular elements .  
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 60
LY3298176Serum  and plasma samples for non -pharmacogenetic bio marker research will be co llected at the 
times specified in the Schedule of Act ivities (Section 2) where local regulat ions allow.
Samples will  be used for research on the drug target, disease process, variable response to 
tirzepat ide, pathways associated with T2DM, obesity, and/or diabet ic com plicat ions, m echanism  
of action of  tirzepat ide, and/or research method, or for validat ing diagnostic tools or assay (s) 
related to T2DM, obesit y, and/or di abetic complications.
All samples will be coded with the subject number.  These samples and any  data generated can 
be linked back to the subject only by the invest igative site personnel.  
Samples will  be retained for a m aximum  of 15 y ears after the last subject visit, or for a shorter 
period if local  regulat ions and/or IRBs impose shorter time limits , at a facilit y selected by  Lilly  
or its desi gnee.  Thi s retenti on peri od enables use of new technologies, response to regulatory  
questions, and invest igation of variable response that may not be observed unt il later in the 
development of tirzepat ide or af ter tirzepat ide is commercially  available .  
9.9. Health Economics
Thissection is not applicable for this study.
9.10. Passive Detection of Eating Activity
To evaluate and refine an eat ing activit y pattern recognit ion model, motion sensor data will be 
collected pass ively  via a wrist -wearable device during the last week of the fo llow
-up peri od of  
the study  (Secti on2; Schedule of Act ivities).
At Visit 12(approximately 3 weeks fo llowing the last dose of study  drug) ,subjects will visit the 
CRU on an outpatient basis, where they  will be provi ded wi th a wrist -wearable device to be 
worn on their dominant arm.  The device will be worn during an ad libitum foo d intake test and 
subjects will then continue to wear the device for a further 4 day s at hom e.  The device shoul d 
always be worn on dominant hand/wrist ( 24/7) on the day
s specified.  
On all days the subject is wearing the device at home (approximately 4 d ays), eating events will 
be detected (food and corresponding utensils, if applicable) in free-living condit ions using the 
Remote Food Photography  Method ©(RFPM) and SmartIntake ®app ( Appendix 5 ).  Energy  and 
gram  intake will not be calculated with the RFPM/SmartIntake ®app, rather, the date and 
timestamp of the eat ing events will be evaluated in relat ion to data from the wrist -worn m otion 
sensor.
At Visit 13(approximately 4 weeks fo llowing the last dose of study  drug) ,subjects will again 
return to the CRU on an outpatient basis.  While the device is st ill being worn, subjects will 
complete an ad libitum food intake test.  Subjects will then be required to return the 
wrist-wearable device to the CRU staff.  
The start and end time of each ad libitum food intake test during the fo llow-up peri od shoul d be 
recorded in the eCRF.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 61
LY329817610. Statistical Considerations and Data Analysis
10.1. Sample Size Determination
The sample size is der ived such that the primary endpo int shall be met . In parti cular, that is to 
compare the change from baseline treatment difference in ad libitum calorie intake during lunch .
The foundat ion for making a reasonable assumpt ion for effect size and vari ability is based on 
both unblinded data fro m I8F-MC-GPGC (Study  GPGC) and blinded data from I8F-MC-GPGT
(Study  GPGT) .Study  GPGC i s a Phase 1 study  to investigate safety , tolerabili ty, PK, and PD of 
tirzepat idesubcutaneously  administered once wee kly to Japanese pat ients with T2DM .Study  
GPGT i s a 28 -week Phase 1 study  designed to examine α and β cell funct ion, insulin sensit ivity, 
glucose and lipid metabo lism, food intake (ad libit um calorie intake during lunch), and energy  
expenditure in pat ientswith T2DM treated with tirzepatide.
Combining the results from Study  GPGC and blinded data fro m Study  GPGT, the estimated 
variabilit y(standard deviat ion) is 289 kcal and the estimated treatment difference between 
placebo and tirzepati de is 212 kcal. Therefore, at least 80% power can be achieved based on 2 
sample t -test using 2-sided test at al pha l evel of 0.05 with asample size of31completers per
arm.Assuming 15% discontinuation rate, approximately 111subjects ( 37subjects per treatment 
arm) are planned to be random ly assigned.
10.2. Populations for Analyses
10.2.1. Study Participant Disposition
A detailed description o f subject disposit ion will be provided at the end of the study . All 
subjects who discontinue from the study  will be identified, and the extent of their parti cipati on in 
the study  will be reported.  If known, a reason for their discont inuation fro m study  will be given.
10.2.2. Study Participant Characteristics
Dem ographic and baseline characterist ics will be summarized by treatment group.  These data 
willbe summarized using standard descript ive statist ics.
10.2.3. Treatment Compliance 
Treatment compliance will be listed and summarized using standard descript ive statist ics.
10.3. Statistical Anal yses
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Company  or its 
designee .
Pharmacodynamic analyses will be conducted on data from all subjects who receiv eat least 
1dose of tirzepat ide, placebo, or liraglut ideand have evaluable P D data .  
Sensit ivity analyses 
may be performed as deemed necessary .  
Safety analyses will be conducted for all enro lled subjects, whether or not they  com pleted all  
protocol  requi rements.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 62
LY3298176Addit ional exploratory  analyses of the data maybe conducted as deemed appr opriate.  
10.3.1. Safety Analyses
10.3.1.1. Clinical Evaluation of Safety
The incidence of AEs for each treatment will be presented by  severi ty and by associ ation with IP 
as perceived by the investigator.  Adverse events reported to occur prior to study  entry  will be 
distinguished from those reported as new or increased in severit y during the study .  Each AE will 
be classified by the most suitable term fro m the medical regulatory  dicti onary .
All AEs and SAEs will be reported.
10.3.1.2. Statistical Evaluation of Safety
Safety param eters that will be assessed include safety  lab param eters (including t irzepat ide 
ADA) , vital signs, TEAEs (including TEAEs of special interest), and SAEs .  
Summary  statistics will be presented by  treatm ent for the safet y measures .  Addit ionally,
statistical analysis may be perform ed if warranted upon review o f the data.
The analysis details will be provided in the SAP .
10.3.2. Pharmacokinetic Analyses
10.3.2.1. Pharmacokinetic Parameter Estimation
Sparse PK samples will be co llected across the 6-week treatm ent durati on according to Section 2
(Schedule of Act ivities).  Tirzepati de concentrations will be determined to support an 
understandin g of tirzepat ide exposure over the treatment duration and compare wi th expected 
tirzepat ide PK.
10.3.2.2. Pharmacokinetic Statistical Inference
No summaries or analyses of PK parameters are planned.   
Tirzepat ide concentrations may be 
summarized by  week .  
10.3.3. Pharmacody namic Analyses
10.3.3.1. Pharmacodynamic Parameter Estimation
Pharmacodynamic parameters will be measured at baseline, Week 3, and Week 6, to assess the 
effect of study  treatm ents on energy intake and central  reward and appeti tecircuits in the brain .  
Param eters are provi ded in Section9.1and additional considerat ions are described below .  
Measures of Appetite and F ood Intake 
Energy intake ass essed by ad libitum food intake test:The p rimary endpoint isenergy  
intake (kcal )during lunch in a clinical setting. The lunchconsist sof a buffet meal , where 
subjects can eat as much or as litt le as they wish .Other food intake variables such as
gram s of carbohydrate, protein, and fat (saturated and unsaturated) consumed , as well as 
the percent of energy  intake (kcal ) from carbohydrate, protein, and fat (saturated and 
unsaturated) may also be com puted if deemed necessary .  
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 63
LY3298176Appet ite VAS:  The VAS scales will be analyzed as continuous variables on the 
0-100 scale for individual co mponents.  Overall appetite score is calculated as the 
average o f the 4individual scores (satiety + fullness + [
100-prosp ective food 
consumption ]+ [100- hunger ]/4) (Flint et al. 2000 ; van Can et al. 2014 ).The higher 
overall appetite score indicates less appet ite and the lower score indicates more appetite .
Measures of Central Reward and Appetite Circuits
BOLD fMRI : Mean percent BOLD signal differences between views of highly palatable 
food (HF-HSand HF-HCCHO ) versus non
-foodobjects (e.g.office supplies, furniture ) 
will be calculated within 5princi pal food reward -related regions of interest; distinct 
locations wit hin the insula, medial frontal  gyrus, superi or temporal  gyrus, precentral  
gyrus, and cingulate gy rus.  Addit ional analysis will examine the BOLD signal 
differences in 4 exploratory  food reward -related regions of interest; the hippocampus, 
putam en, orbi tofrontal  cortex, and ventral striatum .  
Addit ional analyses using other funct ional contrasts ( e.g., Highly Palatable foods versus Not 
Highly Palatable Foods , not highly palatable foods versus nonfood objects ) may  be conducted as 
necessary . Other PD m easures and exploratory  measures will be described in t he SAP .  
10.3.3.2. Pharmacodynamic Statistical Inference
The primary  endpoint will be analyzed using an analysis o f covariance (ANCOVA) to compare 
the effect of tirzepat ide versus placebo at Week 3 on energy  intake wi th term s, treatm ent, 
baseline BMI stratum, and baseline energy  (kcal ) intake as a covariate in the model .  The 
response variable will  be the change from  baseline to Week 3 in energy  (kcal) intake ,as assessed 
by ad libitum food intake test.  
The primary analys is will show l east squares means of energy (kcal) intake by treatment and the 
treatm ent difference of tirzepat ide versus placebo as well as standard error and 95% confidence 
interval .  All tests will  be done at the 2 -sided 0.05 α l evel,unless otherwi se specified.
Analyses for secondary  and expl oratory  endpoints will be specified in SAP .  
10.3.4. Evaluation of Immunogenicity
The frequency and percentage of subjects wi th preexist ing ADA and with TE-ADA +to 
tirzepat idemay be tabulated. Treatment -emergent ADAs are defined as those with a titer 2 -fold 
(1 dilut ion) greater than the minimum required dilution if no ADAs were detected at baseline 
(treatment -induced ADA) or those with a 4 -fold (2 dilut ions) increase in t iter comp ared to 
baseline if ADAs were detected at baseline (treatment -boosted ADA). For the TE -ADA+ 
patients the distribut ion of maximum t iters maybe described.   The frequency o f neutralizing 
antibodies may also be tabulated in TE -ADA+ patients.
The rel ationship between the presence of ant ibodies and the PKparameters and PDresponse 
including safet y and efficacy  to tirzepati demay be assessed.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 64
LY329817610.3.5. Interim Analyses
No interim analyses are planned for this study .  If an unplanned interim analysis is de emed 
necessary , the Lilly CP, CRP /investigator, or designee will consult with the appropriate medical 
director or desi gnee to determine if it is necessary  to am end the protocol .
10.3.6. Exploratory Analysis for Motion Sensor Modeling
An exist ing model for eating a ctivit y recognit ion based on data from wrist -wearable device 
motion sensors (accelero meter and gy roscope) will be applied to classify  time segments as 
involving eating or not.  Classificat ion accuracy of this model will be evaluated relative to the 
ground truth l abels co llected in this study .  Ground truth labels are defined as the meal t imes 
obtained by  the CRU staff during the follow -up peri od days, on which ad libitum food intake 
tests will be performed; a time when the food is weighed before and after t he meal will be used 
as the time of meal start and end, respect ively.  Ground truth will also be obtained on the days 
when subjects use the RFPM and SmartIntake ®app in free -living condit ions, where the 
timestamps associated with food photographs before an d after the m eal will be used as the time 
of meal start and end, respect ively.  
Classificat ion accuracy will be characterized using sensit ivity, specificit y, precision, and area 
under the curve.  
The exist ing m odel will be refined by re -training it with additional data f rom this study .  Data 
collected in this study  will be spli t into training, validat ion, and test datasets to ensure that data 
used in model re -training will not be used in the assessment of the re -trained model accuracy .  
Re-trained model a ccuracy  will be assessed using the same metrics as described above.  
The analyses specified in this sect ion will be detailed in the digital bio marker analysis plan.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 65
LY329817611. References
[ADA] American Diabetes Associat ion. Glycemic targets. Standards of medical care in 
diabetes —2019. Diabetes Care . 201 9;42(Suppl.1):S61-S70 .
Bandini LG, Schoeller DA, Cy r HN, Di etz WH. Validit y of reported energy  intake in obese and 
nonobese adolescents. Am J Clin Nutr. 1990;52(3):421 -425.
Banks PA, Freeman ML. Practice guidelines in acute pancreatit is. Am J Gastroenterol.
2006;101(10):2379 -2400.
Beasley J, Riley  WT, Jean -Mary  J. Accuracy  of a PDA -based dietary  assessment program. 
Nutrition. 2005;21(6):672 -677.
Beaton GH, Burema J, Retinbaug h C. Errors in the interpretation of dietary  assessments. Am J 
Clin Nutr. 1997;65(4 Suppl):11000S -1107S. doi :10.1093/ajcn/65.4.1100S.
Blechert J, Meul e A, Busch NA, Ohla K. Food -pics: an image database for experimental research 
on eating and appet ite. Fron t Psychol. 2014;5 :617.
Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of 
once -weekly semaglut ide on appet ite, energy  intake, control of eat ing, food preference and 
body  weight in subjects with obesit y. Diabetes Obes Metab . 2017;19:1242 –1251.
Brown BM, Peiffer JJ, Martins RN. M ultiple effects of physical act ivity on m olecular and 
cogni tive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's 
disease? Mol Psychiatry. 2013;18(8):864 -
874.
Calanna S, Christensen M, Holst JJ, Laferr ère B, Gl uud LL, Vi sbøll T, Knopp FK. Secretion of 
glucose -dependent insulinotropic polypeptide in patients with ty pe 2 diabetes: a sy stem atic 
review and meta -analysis of clinical studies. Diabetes Care. 2013;36(10):3346 -3352.
Campbell JE, Drucker DJ. Pharmacology , physi ology , and mechanisms o f incretin hormone 
action. Cell Metab . 2013;17(6):818 -837.
Cepeda -Benito A, Gleaves DH, Williams TL, Erath SA. T he development and validat ion of the 
state and trait food-cravings questi onnai res. Behav Ther. 2000;31(1):151 -173.
Coskun T, Sl oop K, Loghin C, Alsina -Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, 
Cabrera O, Roell WC, Kuchibhot la U, Moyers JS, Benson CT, Gimeno RE, D’Alessio DA, 
Haupt A. LY3298176, a no vel dual GIP and GLP -1 receptor agonist for the treatment of ty pe 2 
diabetes m ellitus: From  discovery  to clinical  proof  of concept. Molecular metabolism . 
2018;18:3 - 14.
Columbia Lighthouse Proj ect. Col umbia -Suicide Severi ty Rating Scal e (C-SSRS) website. 
Available at: http://www.cssrs.columbia.edu . Accessed 21 February  2020.
Danne T, Philotheou A, Goldman D, Guo X, Ping L, Cali A, Johnston P. A randomized trial 
comparing the rate of hypoglycemia – assessed using continuous glucose monitoring – in 
125prescho ol children wit h type 1 di abetes treated with insulin glargine or NPH insulin (the 
PRESCHOOL study ). Pediatr Diabetes . 2013;14(8):593 -601.
Farr OM, Sofopoulos M, Tsoukas MA, Dincer F, Thakkar B, Sahin -Efe A, Filippaios A, Bowers 
J,Srnka A, Gavrieli A, Ko BJ,Liakou C, Kanyuch N, Tseleni-Balafouta S, Mantzoros CS.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 66
LY3298176GLP -1receptors exist in the parietalcortex, hypothalamus andmedulla ofhuman brains and 
theGLP -1analogue liraglutide alters brain act ivity related to hi ghly desirable food cues in 
individuals with diabetes: a crossover, randomised, placebo -controlled trial. Diabetologia.
2016;59(5):954 -965.
Farr OM, Upadhyay  J, Rutagengwa C, Di Prisco B, Ranta Z, Adra A, Bapatla N, Douglas VP, 
Dougl ass KAA, Nol en-Doerr E, Matthew H, Mantzoros CS. Longer-term liragluti de 
administration at the highest dose approved for obesit y increases reward- related orbi tofrontal  
cortex activat ion in response to food cues: Implicatio ns for plateauing weight loss in response 
to anti -obesi ty therapies. Diabetes Obes Metab. 2019;21 (11):2459 -2464.
Finan B, Müller TD, Clemmensen C, Perez -Tilve D, DiMarchi RD, Tschöp MH. Reappraisal o f 
GIP pharm acology for metabo lic disease. Trends Mol Med . 2016;22(5):359 -376.
Flint A, Raben A, Blundell JE, Astrup A. Reproducibilit y, power and validit y of visual  anal ogue 
scales in assessment of appetite sensat ions in single test meal studies. Int J Obes Relat Metab 
Disord. 2000;24:38 -48.
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Mili cevic Z, 
Robins D, Haupt A. Efficacy and safet y of LY3298176, a novel dual GIP and GLP -1 receptor 
agonist, in pat ients with type 2 di abetes: a randomised, pl acebo -controlled and act ive 
comparator -controlled phase 2 trial. The Lancet. 2018; 392(10160): 2180 - 2193.
Frias JP, Nauck MA, Van J, Benson C, Bray  R, Cui X,Milicevic Z, Urva S, Haupt A ,Robins D. 
Efficacy and tolerabilit y of tirzepat ide, a dual glucose -dependent insulinotropic peptide and 
glucagon -like peptide -1 receptor agonist in patients with ty pe 2 diabetes: a 12- week, 
rando mized, double -blind, placebo -controlled study to evaluate different dose -escalat ion 
regimens. Diabetes Obes Metab .
2020; Jan 27. doi: 10.1111/dom.13979 .
Geiselman PJ, Anderson AM, Dowdy  ML, West DB, Redm an SM, Smit h SR. Reliabili ty and 
validit y of a macronutrient self -selecti on paradigm and a food preference quest ionnaire. 
Physiol Behav . 1998;63(5):919 -
928.
Hayes MR and Schmidt HD. GLP -1 influences food and drug reward. Curr Opin Behav Sci.
2016;9:66 -70.
Holland D, Kuperman JM, Dale AM. Efficient correction of inho mogenous stati c magnetic 
field-induced distortion in Echo Planar Imaging. Neuroimage .2010;50(1):175 -183.
King JL, Fearnbach SN, Ramakrishnapillai S, Shankpal P, Geiselman PJ, Martin CK, Murray  
KB, Hicks JL, McClernon FJ, Apolzan JW, Carmichael OT. Perceptual Characterization o f the 
Macronutrient Picture System (MaPS) for Food Image fMRI. Front Psy chol.2018;26(9):17. 
Kirby  KN and Finch JC. The hierarchical structure of self -reported im pulsivi ty.Pers Individ Dif. 
2010;48(6):704 -713.
Kirby  KN and Marakovic NN. Delay -discount ing probabilist ic rewards: Rates decrease as 
amounts increase. Psychon Bull Rev. 1996;3(1):100 -104.
Koizumi M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M, 
Kimura Y, Takeda K, Isaji S, Otsuki M, Matsuno S; JPN. JPN Guidelines for the management 
of acute pancreatit is: diagnostic criteria for acute pancreat itis. J Hepatobiliary Pancreat Surg.
2006;13(1):25 -32.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 67
LY3298176Kroenke K, Spitzer RL, Williams JB. The PHQ- 9: validit y of a brief depressio n severit y 
measure. J Gen Intern Med . 2001;16(9):606 -613.
Lowe MR, Butryn ML, Didie ER, Annuziato RA, Thomas JG, Crerand CE, Ochner CN, Coletta 
MC, Bellace D, Wallaert M, Halford J. The Power Food Scale. A new measure of the 
psycho logical influence of the food environment. Appetite. 2009;53(1):114 -118.
Luppino FS, de Wit LM, Bouvy  PF, Stijnen T, Cuijpers P, Penninx BW, Zit man FG. 
Overweight, obesit y, and depressio n: a systemat ic review and meta -analysis of lo ngitudinal 
studi es. Arch Gen Psychiatry. 2010;67(3):220 -229.
Martin CK, Correa JB, Han H, Allen HR, Rood J, Champagne CM, Gunturk BK, Bray  GA. 
Validit y of the Rem ote Food Photography  Method (RFPM) for estimat ing energy and nutrient 
intake in near real -time. Obesity (Silver Spring). 2012;20(4):891 -
899.
Martin CK, Han H, Coulon Sm, Allen HR, Champagne CM, Anton SD. A novel method to 
remotely  measure food intake of free -living individuals in real t ime: the remote food 
photography  method. Br J Nutr. 2009;11(3):446 -456.
Martin CK, Coul on SM, Markward N, et al. Associat ion between energy  intake and viewing 
television, distracti bility, and mem ory for advertisem ents. Am J Clin Nutr .2009;89:37 –44.
Martin CK, Rednam LM, Zhang J, et al. 
Lorcaserin, a 5-HT 2Creceptor agonist, reduces body  
weight by  decreasing energy  intake wi thout influencing energy  expendi ture. J Clin Endocrinol 
Metab .2011; 96:837 -845.
Martin CK, O’Neil PM, Pawlow L . Changes in food cravings during low -calorie and very -low-
calorie diet s. Obesity .2006;14(1) :115- 121 .
Moreno S, Rodriguez S, Fernandez MC, Tamez J, Cepeda -Benito A. Clinical validat ionof 
thetraitandstate versio nsof the Food Craving Questionnaire . Assessment . 
2008;15(3):375 -387.
Nauck MA, Frossard J -L, Barkin JS, Anglin G, Hensley  IE, Harper KD, Milicevic Z. 
Assessment of pancreas safety  in the development program of once -weekly GLP -1 receptor 
agonist dulaglut ide. Diabetes Care . 2017;40(5):647 -654.
Nauck MA, Meier JJ. GIP and GLP -1: Stepsiblings Rather Than Monozygotic Tw ins Within the 
Incretin Family . Diabetes. 2019;68(5):897 -900.
Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with ty pe 2 di abetes: 
physio logy, pathophysio logy, and response to therapeutic interventions . Lancet Diabetes 
Endocrinol. 2016;4(6):525 -536.
Patton JH, Stanford MS, Barra tt ES. Factor structure of the Barratt impulsiveness scale. J Clin 
Psychol. 1995;51(6):768 -774.
Reid RC, Cy ders MA, Moghaddam JF, Fong TW. Psychometric properties of the B arratt 
impulsiveness scale in pat ients with gambling disorders, hy persexualit y, and 
methamphetamine dependence. Addict Behav . 2014;39(11):1640 -1645.
Saxenda [package insert]. Plainsboro, NJ: Novo Nordisk, 2018.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 68
LY3298176Steinberg WM, Buse JB, Ghorbani MLM, Ørsted DD, Nauck MA; LEADER Steeri ng 
Committee; LEADER Tri al Invest igators. Amylase, lipase, and acute pancreat itis in people 
with type 2 diabetes treated with liraglut ide: result s from the LEADER Rando mized Trial. 
Diabetes Care. 2017a;40(7):966 -972.
Steinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, DeVries JH. Impact of 
liraglutide on amylase, lipase, and acute pancreat itis in part icipants wi th overwei ght/obesi ty 
and normoglycemia, prediabetes, or ty pe 2 di abetes: secondary  analyses of pool ed data from 
the SCALE clinical develo pment program . Diabetes Care. 2017b;40(7):839 -848.
Stunkard AJ and Messick S. Eating Inventory  Manual  (The Psychol ogical Corporati on). 1988.
San Antonio, TX: Harcourt Brace & Company.
Stunkard AJ and Messick S. The three- factor eating questionnaire eto mea sure di etary  restraint, 
disinhibi tion and hunger. J Psychosom Res .1985;29(1):71 -83.
Tang DW, Fellows LK, Small DM, Dagher A. Food and drug cues activate similar brain regio ns: 
a meta-analysis o f functional MRI studi es. Physiol Behav. 2012;106(3):317 -324.
ten Kulve JS, Veltman DJ, van Bloemendaal L, Barkhof F, Drent ML, Diamant M, Ijezerman 
RG. Liragluti de Reduces CNS Act ivation in Response to Visual Food Cues Only After 
Short -term Treatm ent in Pati ents wi th Type 2 Di abetes. Diabetes Care. 2016;39(2):214 -224.
Tran KM, Johnson RK, Soultanakis RP, Matthews DE. In-person vstelephone -administered
multiple-pass 24-hour recalls in wo men: validation with doubly  labeled water. J Am Diet 
Assoc. 2000;100(7):777 -
783.
Schoeller DA, Bandini LG, Dietz WH. Inaccuracies i n self -reported intake i dentified by 
comparison wi th the doubly  labelled water m ethod. Can J Physiol Pharmacol.
1990;68(7):941 -949.
Stone AA, Shiffman S. Ecological mo mentary  assessment (EMA) in behavioral medicine. Ann 
Behav Med .1994;16(3):199 -202. 
[USDA] United States Department of Agriculture. United States Department of Agriculture, 
Agricultural Research Service. 2018. USDA Food and Nutrient Database for Dietary Studies 
2015-2016.
van Bloemendaal L, IJzerman RG, ten Kulve JS, Barkhof F, Konrad RJ, Drent ML, Veltman 
DJ,Diamant M. GLP -1 receptor activat ion modulates appeti te-and reward -related brain areas 
in humans. Diabetes. 2014;63(12):4186 -
4196.
van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once -daily  GLP -1 
analog li raglut ide on gastric empt ying, glycemic parameters, appetite and energy metabo lism 
in obese, non -diabet ic adults. Int J Obes . 2014;38(6):784 -793.
Weinberg ME, Bacchetti P, Rushakoff RJ. Frequent ly repeated glucose measurements 
overestimate the incidence of inpatient hy poglycemia and severe hyperglycemia. J Diabetes 
Sci Technol . 2010;4(3):577 -582.
White MA, Whisenhunt BL, Williamson DA, Greenway FL, Netemeyer RG. Development and 
validat ion of the food -craving inventory .Obes Res. 2002;10(2):107 -114.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 69
LY3298176Williams on DA . Digital photography : A new method for estimat ing food intake in cafeteria 
settings. Eat Weight Disord. 2004;9(1):24 -28.
Williamson DA, Allen HR, Martin PD, Alfo nso AJ, Gerald B, Hunt A. Comparison of digital 
photography  to wei ghed and visual estimat ion of porti on si zes. J Am Diet Assoc .
2003;103(9):1139 -1145.
Womble LG, Wadden TA, Chandler JM, Martin AR. Agreement between weekly vs. daily 
assessment of appetite. Appetite. 2003;40(2):131 -135.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 70
LY329817612. Appendices
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 71
LY3298176Appendix 1. Abbreviations and Definitions
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 72
LY3298176Term Definition
ADA anti-drug antibody
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An AE can therefore b e any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
ALP alkal ine phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
BAT basophil activation test
BIS Barratt Impulsiveness Scale
blinding A procedure in which one or more parties to the study are kept unaware of the treatment 
assignments.  Unless otherwise specified, blinding will remain in effect until final database 
lock.
A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the subject is not, or vice versa, or when the sponsor is aware of t he treatment 
but the investigator and/his staff and the subject are not.  A double -blind study  is one in 
which neither the subject nor any of the investigator or sponsor staff who are involved in 
the treatment or clinical evaluation of the subjects are awa re of the treatment received
BMI body mass index
BOLD blood oxygen ationlevel dependent
CAT computer adaptive test
CBF cerebral blood flow
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable re gulatory  requirements.
confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the data and that Lilly is confident that results are accurate.  
Confirmation will either occur i mmediately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
CP Clinical Pharmacologist
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 73
LY3298176CRP Clinical Research Physician:  Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician or other medical officer.
CRU clinical research unit
C-SSRS Columbia -Suicide Severity Rating Scale
CT computed tomography
ECG electrocardiogram
eCRF electronic case report form
enroll The act of assigning a subject to a treatment.  Subjects who are enrolled in the study are 
those who have been assigned to a treatment.
ET early  termination
FCI Food Craving Inventory
FCQ -S Food Craving Questionnaire -State
fMRI function almagnetic resonance imaging
GCP good clinical practice
GI gastrointestinal
GIP glucose -dependent insulinotropic
GIPR glucose -dependent insulinotropic receptor
GLP-1 glucagon -like peptide 1 
GLP-1R glucagon -like peptide1 receptor
GLP-1RA glucagon -like peptide 1 receptor agonist
HCV hepatitis C virus
HCCHO high carboh ydrate
HF high fat
HIV human immunodeficiency virus
HP high protein
HS high sugar
IB Investigator’s Brochure
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 74
LY3298176informed 
consent/informed 
consent form (ICF)Aprocess by which a subject voluntarily confirms his or her willingness to participate in a 
particular study, after having been informed of all aspects of the study that are relevant to 
the subject’s decision to participate.  Informed consent is documented by means of a 
written, signed and dated informed consent form .  
ICH International Council for Harmoni sation
Ig immunoglobulin
IP investigational product:  A pharmaceutical form of an active ingredient or placebo being 
tested or used as a reference in a clinical study, including products already on the market 
when used or assembled (formulated or packaged) in a way different from the autho rized 
form, or marketed products used for an unauthorized indication, or marketed products used 
to gain further information about the authorized form.
investigator A person responsible for the conduct of the clinical study at a study site.  If a stu dy is 
conducted by a team of individuals at a study site, the investigator is the responsible leader 
of the team and may be called the principal investigator.
IRB institutional review board
Legal 
RepresentativeAn individual or judicial or other body aut horized under applicable law to consent, on 
behalf of a prospective subject, to the subject’s participation in the clinical study.
LCCHO low carboh ydrate
LF low fat
LP low protein
MAD multiple ascending dose
MEN 2 multiple endocrine neoplasia syndrome type 2
MRI magnetic resonance imaging
MTC medullary thyroid carcinoma
NPAL not highly palatable
open label A study  in which there are no restrictions on knowledge of treatment allocation, therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
PAL Highly palatable
PD pharmacodynamic
PHQ -9 Patient Health Questionnaire -9
PFS pre-filled syringe
PG plasma glucose
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 75
LY3298176PK pharmacokinetic
QD once daily
QW once weekly
randomize the process of assigning subjects/patients to an experimental group on a random basis
RFPM Rem ote Food Photography Method ©
SAD single ascending dose
SAE serious adverse event
SAP statistical analysis plan
SC subcutaneous(ly)
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study .  
SUSAR suspected unexpected serious adverse reaction
T2DM type 2 diabetes mellitus
TBL total bilirubin
TE-ADA treatment -emergent anti -drug antibody
TEAE treatment -emergent adverse event:  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state , and does not necessarily have to have a causal relationship with this 
treatment 
ULN upper limit of normal
VAS visual analog scale
WOCBP women of childbearing potential
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 76
LY3298176Appendix 2. Clinical Laboratory  Tests
Safety Laboratory Tests
Hematology Clinical Chemistry
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Bicarbonate
Mean cell volume Chloride
Mean cell hemoglobin Calcium
Mean cell hemoglobin concentration Phospho rus
Leukocytes (WBC) Glucose (fasting) a
Absolute counts of Blood urea nitrogen
Neutrophils Uric acid
Lymphocy tes Total protein
Monocytes Albumin
Eosinophils Total bilirubin
Basophils Alkaline phosphatase
Platelets Alanine aminotransferase
Aspartate aminotransferase
Urinalysis Creatinine
Specific gravity Lipase (fasting)
pH Amylase
Protein Triglycerides (fasting) a
Glucose Total cholesterol (fasting)
Ketones Low-density  lipoprotein (fasting)
Bilirubin High -density lipoprotein (fasting)
Urobilinogen Hemoglobin A1c
Blood
Leukocytes Serology e
Microscopy b Hepatitis B surface antigen
Hepatitis C antibody, hepatitis C RNA
HIV antibody
Endocrine
FSH b, c Pregnancy test (urine, serum) f
Calcitonin d Drug and alcohol screen g
Abbreviations:  FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus; RBC = red blood cells; 
WBC = white blood cells.
aAt timepoints when glucose and triglyceride efficacy assessments coincide with safety laboratory tests, glucose 
and triglycerides will only be analyzed once .  
bIf clinically indicated, as per inves tigator’s discretion .
cFemale subjects only .
dAt screening only
eAt screening only (unless previously performed within the last 6 months with reports available for review).   See 
exclusion criteria (Section 6.2) for further details .  
fPerformed for women of childbearing potential only.  Serum pregnancy test is done at screening and follow -up 
and urine pregnancy test is performed on Day s -4, 1, 15, and 36.
gPerforme d at screening.  Procedures may be repeated throughout the study as deemed necessary by the 
investigator.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 77
LY3298176Appendix 3. Study  Governance, Regulatory  and Ethical 
Considerations
Informed Consent
The invest igator is responsible for:
ensuring that the subject understands the nature of the study ,the potential risks and 
benefits of part icipating in the study , and that thei r parti cipat ion is vo luntary.
ensuring that informed consent is given by each subject or legal representative.  This 
includes obtaini ng the appropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the administration of invest igational 
product.
answering any quest ions the subject may  have throughout the study  and sharing in a 
timely  manner any  new inform ation that m ay be relevant to the subject ’swillingness to 
continue his or her participat ion in the study .
provi ding a copy  of the ICF to the subject or the subject’s legal representative and 
retaining a copy  on file .
Recruitment
Lilly or i ts desi gnee is responsible for the central recruit ment strategy  for pati ents.  Individual 
investigators may have addit ional local requirements or processes.   Study -specific recruit ment 
materi al should be approved by Lilly .
Ethical Review
The inve stigator must give assurance that the institutional review board ( IRB) was properly 
constituted and convened as required by ICH guidelines and other applicable laws and 
regul ations.
Docum entati on of  IRB approval o f the protocol  and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te.  Lilly or its representatives must approve the ICF 
before i t is used at the invest igative site.  All ICFs must be compliant with the ICH guideline on 
GCP.
The study  site’s IRB shoul d be provi ded wi th the following:
the current IB and updates during the course of the study
ICF
relevant curri cula vi tae
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 78
LY3298176Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol and with :
1)consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council for International 
Organizat ions of Medical Sciences (CIOMS) Internat ional Ethi cal Guidelines 
2)applicable ICH GCP Guidelines 
3)applica ble laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third-party  organi zation.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, t he protocol accurately describes the planned design and conduct of the 
study .  
After reading the protocol, theprincipal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
Final Report Signatur e
The invest igator or designee will sign the clinical study report for this study, indicat ing 
agreem ent wi th the analyses, results, and conclusio ns of the report.
The sponsor’s responsible medical o fficer and statistician will sign/approve the final clinic al 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  site, as appropri ate.
provi de training to i nstruct the invest igators and study  coordinators.  This training will 
give instruction on the protocol, the complet ion of the eCRFs, and study  procedures.
make periodic visit s to the study  site.
be available for consultation and stay  in contact with the study  site personnel by  mail, 
telephone, and/or fax.
review and evaluate eCRF data and/or use standard computer edits to detect errors in data 
collection.
conduct a qualit y review of the database .
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 79
LY3298176In addit ion, Lilly or its representatives will periodically check a sample of the subject data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly and/or 
regul atory  agencies at any  time.  Invest igators will be given notice before an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will p rovide the sponsor, 
applicable regulatory  agencies, and applicable IRBs wi th direct access to the original source 
docum ents.
Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this study .  The si te must define and retain al l 
source records and must maintain a record of any  data where source data are directly entered into 
the data capture system.
Data Protection
Data systems used for the study  will have control s and requi rements in accordance wit h local 
data protecti on law.  
The p urpose and use of subject personal informat ion collected will be provided in a written
docum ent to the subject by the sponsor .
Study and Site Closure
Discontinuation of Study Site
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , the invest igator, or the IRB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be di scontinued if Lilly or its designe e judges i t necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 80
LY3298176Appendix 4. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and estimated blood volumes 
forall blood s ampling (screening, safet y laboratories, and bioanalyt ical assays) during the study .  
Protocol I8F-MC -GPHH Sampling Summary
PurposeBlood Volume per 
Sample (mL)Number of Blood 
SamplesTotal Volume 
(mL)
Screening tests a,b 24 1 24
Safety laborato ry tests a,b 22.5 4 90
Tirzepatide PK 3 5(+3) 24
Pharmacodynamics
Ghrelin (fasting )c 2 3 6
Glucagon (fasting) c 2 3 6
Glucose (fasting) –Weeks 3 and 6 c 2 2 4
Triglycerides (fasting) –Weeks 3 and 6 c 2.5 2 5
Insulin (fasting) c 2.5 3 7.5
Insulin (postprandial) c 2.5 3 7.5
Peptide YY ( postprandial )c 5 3 15
Pancreatic polypeptide (postprandial )c 5 3 15
Leptin (postprandial )c 4 3 12
Active GIP and GLP -1 (postprandial )c 2 3 6
Amylin ( postprandial )c 5 3 15
Immunogenicity 10 4(+3) 70
Pharmacogenetics 10 1 10
Nonpharmacogenetic stored sample c(fasted) 11 3 33
Total 350
Total for clinical purposes [rounded up to nearest 10 mL] 350
Abbreviations :GIP = glucose -dependent insulinotropic polypeptide; GLP -1 = glucagon -like peptide 1; 
PK=pharmacokinetics .
aadditional samples may be drawn if needed for safety purposes.
bperformed on site or in a local laboratory.
cperformed at a central or referral laboratory, including for storage.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 81
LY3298176Appendix 5. Pharmacody namic Assessments
5.1.Ad Libitum Food Intake Test
Food intake will be quant ified in a clinical setting .  
5.1.1. Clinic -Based Food Intake Test
Food intake will be quant ified via test meals conducted in the CRU at lunch during the 6 -week 
treatm ent peri od (Baseline, Day -4 to Day -1), Day 16 [ Week 3, Visit 6], and Day  37 [Week 6, 
Visit 11]), and during the thirdand fourth week sof the fo llow -up peri odi.e.[Visit 12]and [Visit 
13],respectively . The start time of the lunch test meals will be consistent within subjects across 
testing occasio ns.  
Start and end times of the test meals will be recorded.  
Subjects will co mplete a test l unch that begins between approximately  11:30 AM and 12:30 PM .  
Lunch will consist of buffet m eal (Table GPHH. 3).
Table GPHH. 3
. Details of Buffet Meal
baked potato chips grilled chicken bites barbeque sauce
baked tortilla chips popcorn chicken bites sweet and sour sauce
corn chips cheddar cheese M&M’S ®
pretzel twists swiss cheese crème -filled chocolate cake rolls
buttered popcorn salsa raisins
mixed nuts with salt fat-free ranch dressing fruit punch
baby carrots cheese dip water
Subjects will be instructed that they  can eat as m uch or as little as they  wish during the test meals 
and that they  shoul d alert a staff member when they  are finished eat ing, at which t ime the 
subjects will leave the test meal. Staff members will check on the subjects after 25 minutes and 
terminate the sessio n after 40 minutes if the subject does not end the sessio n.
Food intake will be quant ified by precisely weighing foods before and after the test meals , as 
close to the beginning and end of the meal as possible .  During the fo llow-up peri od, the time the 
food is weighed before and after the test meals will be recorded.  Energy  and nutrient intake will 
be calculated by  linking each food to a m atch in the United States Department of Agriculture 
(USDA) Food and Nut rient Database for Dietary  Studi es (FNDDS) Studies (USDA 2018) or 
data from  the f ood producer/m anufacturer .  
5.1.2. Free -Living Food Intake
The time of mea ls will be assessed for approximately 4 days during the last week of fo llow-up 
period (beginning approximately 3 weeks post -final dose of study  drug). During the fo llow-up 
period, energy  and gram  intake will  not be calculated, rather, the start and stop times of the meal 
will be quant ified based on the timestamps of the food images . These data will becollected with 
the Remote F ood Photography  Method ©(RFPM) (Martin et al. 2009, 2013) and SmartIntake ®
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 82
LY3298176smartphone app lication (or app) . The RFPM and SmartIntake ®app were developed by Corby  
Martin, Ph.D., H. Raymond Allen, Ph.D., and colleagues at the Pennington Bio medical Research 
Center. RFPM data are collected with the SmartIntake ®app, which is used to streamline data 
collect ion and minimize subject burden. 
Self-report m ethods, such as pen -and-paper and dietary  recall, rely on the abilit y of the subject to 
accurately recall the t ypes and portion sizes of foods consumed, and the accuracy o f these 
methods have been quest ioned(Beaton et al . 1997; Tran et al . 2000; Schoeller et al. 1990; 
Bandini et al. 1990) .Importantly , ~50% of the error in self -report m ethods i s due to subjects’
inabilit y to accurately  estimate porti on size (Beasley  et al . 2005) , a limitat ion that i s avo ided 
when using the RFPM and SmartInta ke®app.  
The RFPM and SmartIntake ®app also resul t in the collect ion of data in real -time withfood 
image data which can be evaluated via a password protected website for qualit y and 
completeness; thus, providing a platform to reduce missing data and fac ilitate data qualit y.
When using the SmartIntake ®app, subjects place a reference card next to their food and capture 
images of their food select ion and pl ate waste. The user identifies foods that are not easily 
ident ified by wrappers or con tainers by t yping a food descript ion into a text box. Drop -down 
boxes also allow the user to indicate what meal or snack is being consumed, and also where the 
food was obtained (e.g., home prepared, restaurant) and where it is being eaten. These data and 
food images a re autom atically and wi relessly  sent by  the app to the server -based Food 
Photography  Applicat ion©, which is used to manage the data collect ion process and analyze the 
food images to estimate energy  and nutri ent intake .  
To facilitate data qualit y and com pleteness, the SmartIntake ®app includes Ecological 
Momentary  Assessment (EMA) methodology (Stone et al. 1994) to remind subjects to capture 
images of the foods and beverages that they  consume. These reminders are text me ssages that 
are scheduled for delivery  at the personalized meal -times of the subjects . The responses to 
EMAs are tracked in near real time, which allows the research team to quickly  identify when 
data collect ion probl ems occur. In such cases, a back -up m ethod i s used (e.g., a food record or 
food recall conducted by  phone). The content of the text reminders can be customized by the 
researcher or clinician.  
The Sm artIntake® app sends subjects’ food images and acco mpanying food descript ions to a 
Pennington server where the Pennington team analyzes the images to estimate food intake if 
needed . The analysis process relies on the Food Photography Applicat ion©, which allows the 
operator to identify a match for each food from the Food and Nutrient Database for Dietary 
Studi es (USDA 2018) and other sources, such as manufacturer’s informat ion and Nutri tion Fact 
Panels, to calculate energy and nutrient intake. Addit ionally , the operator uses the program to 
estimate portion size by visual ly com paring subjects’ food images to images of foods with a 
known portion size (i.e., standard portion images). This process relies on exist ing and validated 
methodol ogy(Martin et al. 2012, Martin et al. 2009, Williamson et al. 2004; Williamson et al. 
2003) to estimate food selected and plate waste, which is used to calculate food intake by 
difference. The RFPM has been found to accurately measure the energy and nutrient intake of 
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 83
LY3298176adults, wi th error of 3.7% over 6days in free -living condi tions com pared to the gol d standard, 
doubly  labeled water.
During the current study , subject s will be trained how to use the RFPM and SmartIntake ®app 
during their visit to the center to capture imaging data on Day  59.    All food consumption during 
the observat ion peri od shoul d be recorded and subjects will receive regular reminders and 
extensive review of their data in near real time to foster data qualit y and com pleteness. These 
procedures will facilitate data collection as a formal run- in is not being conducted befor e data 
collect ion begins.   Subjects will be instructed to photograph their food as closely as possible to 
the actual  meal start and end .  
5.2Magnetic Resonance Imaging
Funct ionalneuroimaging, in the forms of BOLD fMRI will be used to assess brain response 
patterns to food and non-food images . The MRI scanning will occur on different scanners such 
asa 3T General Electric Discovery 750W wit h 32-channel head co il, a 3T General  Electric 
Discovery  750 wi th 32-channel head c oil, a 3T Si emens Prisma with a 64 -channel head co il, or a 
3T Philips Achieva with a 32 -channel head coil . Functional neuroimaging sessio n will be 
conducted after participants fast overnight for at least 8 hours (ten Kulve et al . 2016).   
Subjects will be requi red to com plete the food image task during the BOLD f MRI scan.  The 
food image task was developed using images fro m the Food- pic database (Blechert et al. 2014 ).
Briefly, 90food images across sweet and savory  tastes, hi gh-and low -energy  densi ty, and varied 
macronutrient composit ion, were included along wit h 15 images o f non- food obj ects (e.g.
everyday househo ld objects ). This results in 105 images in total. Macronutrient categories 
(Geiselman et al . 1998 ) were made by categorizing each food as:
low versushighfat (LF vs HF, <30% vs >30%)
low versushigh sugar (LS vs. HS, <30% vs. >30%) 
low versus high carbohydrate (LCCHO vs HCCHO, <30% vs >30%)
low versus high protein (LP vs HP, <13% vs >13%)   
This resulted in 6 food categories with 15 photos i n each: 
1.HF/HS
2.HF/HCCHO
3.HF/LCCHO/HP
4.HS/LF
5.LF/HCCHO
6.LF/LCCHO/ HP
Each 600 × 450 color photo shows 1 food on a white background.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 84
LY3298176Among the 6 food categories, HF -HS and HF -HCCHO will be called highly  palatable (PAL) 
food and LF -LCCHO- HP will be called not highly palatable (NPAL) food.
In each tri al of the task, 1food photo is displayed for 5 seconds followed by  0.5seconds of a 
fixation crosshair. Next, the same image scaled to 80% of the original size is shown wit h the 
words “How m uch do y ou want to eat this?” for 2.5 seconds .A slider bar with “Not at all” and 
“Want very  much” on the l eft and ri ght ends appears. The subject moves a jo ystick to select a 
slider bar posit ion and clicks a jo ystick button to respond. A fixat ion crosshair displays for a 
minimum o f 1.5seconds before the next trial. There are 15 trials (i.e. 15 photos) per block and 
14 inter -trial intervals per block: an average of 150 s/block. This is followed by a 30 s inter -
block interval before the next block. total of 7 blocks and 6 in ter-block intervals: 20.5 minutes of 
recorded data. Prior to the beginning o f the task, subjects will be given time to practice the task 
in the scanner . Addi tionally, a high -resolution structural  scan will be acquired. Thetotal durati on 
of each MRI sessio nwill be around 40 minutes.
For the purposes of evaluat ing inter-scanner variabilit yto ensure that the fMRI data from  all sites 
can be analyzed co llectively at the end of the study , subjects will be required to complete a 
bilateral  hand squeeze mot or task during the BOLD fMRI scan, consist ing of 4blocks after the 
food image task. Each block will consist of 30 seconds of bilateral hand squeezing fo llowed by  
30 seconds of rest (around 3 minutes total run t ime). 
To m odel respi ratory  and cardi ac effec ts on the BOLD signals, participants will be fitted wi th a 
lap belt and pulse oximeter.  The respiratory  cycle si gnal and cardiac cycle signal will be 
regressed out of all time series data .  
BOLD fMRI Data Processing
The BOLD fMRI acquisit ion parameters include repetit ion time of 3000 ms, echo time o f 30 ms, 
flip angle of 90 °, slice thickness of 3.5 mm, and 64× 64 image matrix .  
As in prior work (King et al. 2018), a T1-weighted magnet ization-prepared 180° radio -frequency 
pulses and rapi d gradi ent-echo ( MPRAGE )will be collected as an anatomical reference for 
funct ional data .  
Preprocessing o f fMRI data will be done by a n external imaging laboratory  services provi der.
For the hand squeezing fMRI task, BOLD contrasts of hand squeezing versus rest ingwithin 
bilateral  som atom otor ROIs will be calculated. For the food image fMRI task, h ighly palatable 
food (HF-HS, HF-HCCHO ), not hi ghly palatable foods ( LF-LCCHO -HP), and non -food obj ect 
blocks will be modeled. To assess brain act ivation related to vi ewing food pi ctures, the con trast 
between highly  palatable foods and non -food objects will be co mputed. Addit ionally , the 
contrast between highly  palatable foods and not highly  palatable foods as well as the contrast 
between not highly palatable foods and non- food objects m ay be com puted. Contrasts between 
each specific food category  and non -food obj ects may also be computed if deemed necessary . 
Average BOLD contrast in each of 9 areas associated to brain reward will be reported (insula, 
medial frontal gy rus, superi or tem poral  gyrus, precentral  gyrus, cingulate gyrus, hippocam pus, 
putam en, orbi tofrontal  cortex, and ventral striatum). 
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 85
LY32981765.3.Appetite Visual Analog Scale s
The aim of the appet ite visual analog scale ( VAS) is to determine the effects of study  treatm ents 
on appeti te sensat ions and desire for specific foods.  Two ty pes of VAS will be used to assess 
subjective ratings of appet ite and affect; laboratory -based and retrospective.
5.3.1. Appetite Visual Analo g Scale
During the l aboratory -based test meals on (Baseline, Day -4 to Day  -1), Day  16 [Week 3, Vi sit 
6], and Day  37 [Week 6, Visit 11]), subjects will complete VAS ratings immediately before and
after the test l unch.  
Subjects will be asked to rate their feelings of hunger, satiet y, fullness, prospective food 
consumption, and desire for specific foods on a 10 -cm (100 -mm) line, or a 100 -unit line 
represented on a piece of paper ; anchored by  verbal  descriptors, usu ally “not at all” and 
“extrem ely.”  The ratings will include the following 8 questions (Flint et al. 2000):
How hungry  do y ou feel
 right now?
How satisfied do y ou feel right now?
How full do y ou feel right now?
How m uch food do y ou think y ou coul d eat ri ght now?
Would you like to eat som ething sweet?
Would you like to eat som ething salt y?
Would you like to eat som ething savory ?
Would you like to eat som ething fatty?
Pen-and-paper VAS will be used and will include a 10 -cm line.  Subjects will record the irrating 
on the respect ive lines, ranging fro m 0 (“not at all”) to 100 (“extremely”).  Only provided or 
printed (not copied) paper VAS can be used, as copying them alters the length line.  
Overall appet ite score is calculated as described in Secti on10.3.3.1 (Pharm acodynamic 
Param eter Estimat ion).
5.3.2. Retrospective Appetite Visual Analog Scale
Visual anal og score will  be used to m easure average ratings of appet ite that subjects experienced 
over the past week.  These ratings will occur on Baseline, Day -4to Day  -1, Day  16 [Week 3, 
Visit 6], and Day  37 [Week 6, Vi sit 11]).
The retrospective method of co llecting VAS data has been found to be consistent with daily 
assessments of sat iety (Womble et al. 2003).  These VAS items will assess 4 appet ite
-related 
metri cs and the instructi ons to the subjects will be modified, as detailed here: 
How hungry  did y ou feel  over the past week?
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 86
LY3298176How satisfied did y ou feel  over the past week?
How full did y ou feel over the past week?
How m uch food di d you think y ou coul d eat over the past week?
In addit ion to the 4 appetite metrics noted above, retrospective VAS wil l also be used to quantify  
feelings of nausea, malaise, and gastrointest inal distress over the previous week.  Specifically, 
the following i tems will be administered:
How m uch nausea did y ou have over the past week?
How m uch m alaise di d you have over the p ast week?
How m uch gastrointest inal distress did you have over the past week?
These 3 items will be anchored with verbal descriptors ranging fro m “none at all” to “an extreme 
amount”.  
5.4.Food Intake -Related Questionnaires
Subjects’ a ttitudes towards f ood will be evaluated with the Food Craving I nventory  (FCI), Food 
Craving Q uestionnaire -State(FCQ -S), Eating Inventory , and Power of Food Scale.  Thesefood-
related questi onnaires will be administ ered at Day -4 to Day  -1 [baseline ], Day  16 [Week 3, Vi sit 
6], and Day  37 [Week 6, Visit 11]).   Attempts will be made for questionnai res to be completed in 
a fasted state shortly after arriving to the study  site.  
5.4.1. Food Craving Inventory
The 33- item FCI(White et al. 2002) will be used to measure cravings for specific food groups. 
The m easure consists of 5 empirically derived factors: 
high fats
sweets
carbohydrates/starches
fast food fats
and fruits and vegetables
The FCI is scaled in a frequency  format assessing the fre quency  of cravings for parti cular foods 
over the past month. All items are scored in the following manner: Never = 1, Rarely = 2, 
Sometimes = 3, Often = 4, Always = 5. 
The instructions for the FCI will be altered for Day s16 and 37 (Week 3, Visit 6andWeek 6, 
Visit 11) to include the fo llowing time frame: “ Since the last time y ou com pleted thi s 
questionnaire , how often have y ou experienced a craving for the food?”.  This differs from the 
original  instructi ons which denotes a 1 -month time frame.  All ot her instructions on the FCI will 
remain the same as the original . 
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 87
LY32981765.4.2. Food Craving Questionnaire -State
The FCQ -S is a 15 -item measure that assesses the strength of state food cravings at the mo ment
of administrati on.  The FCQ -S has demo nstrated good validit y and internal consistency  in 
non-clinical populat ions at the mo ment of provisio n (Cepeda -Benito et al . 2000; Moreno et al. 
2008).  
Desire, anticipation posit ive, ant icipation negat ive, lack of c ontrol , and hunger scores are 
measured.  Greater scores for each sub -scale denote higher levels o f craving.
5.4.3. Eating Inventory
The Eating Inventory  is a 51 -item validated questionnaire that assesses 3 eating -related 
constructs: 
dietary  restraint 
disinhibi tion 
perceived hunger (Stunkard and Messick. 1985; Sunkard and Messick 1988) 
Dietary  restraint refers to the intent and abilit y to restri ct food intake, di sinhibi tion measures the 
tendency to overeat, and hunger measures suscept ibilit y to feelings of  hunger. Scores for 
restraint, disinhibit ion,and hunger range from 0 to 21, 0 to 18,and 0 to 14, respectively, and a 
greater number indicates greater levels o f each respective eat ing co mponent.
5.4.4
. Power of Food Scal e
The Power of Food S cale measures appetite for palatable foods in the environment at the 
following 3levels of food proximit y: food available , food present , and food tasted .  The Power 
of Food Scale has adequate internal consistency  and test -retest reliabilit y(Lowe et al . 2009).
5.5. Impulsivity
Impulsivit y will be measured wi th the Barratt Im pulsiveness Scale (BIS) on Day -4 to Day  -1 
[baseline], Day  16 [Week 3, Visi t 6], and Day  37 [Week 6, Vi sit 11]). Attempts will be made for 
BIS questi onnai re to be com pleted in a fasted state shortly after arriving to the study  site.
5.5.1. Barratt Impulsiveness Scale
The BISis a 30 -item self-report m easure describing impulsive or non -impulsive behaviors and 
preferences. The scale consists of 6 first order factors as follows : 
attenti on
cogni tive stabilit y
motor
perseverance
self-control
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 88
LY3298176cogni tive co mplexity
The scale also consists of 3 second -order factors:  a ttenti onal, motor, and non-planning. 
The i tems are rated on a 4 -point scal e with responses ranging from  1 = rarely/n ever to 4 = almost 
always /always. The m easure assesses the personalit y/behavioral construct of impulsiveness and 
has demonstrated good psy chometric properti es in mult iple populat ions(Patton et al. 1995; Reid 
et al. 2014) .
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 89
LY3298176Appendix 6. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Evaluat ion of subjects with treatment -emergent abnorm al hepatic biochemical tests during a 
clinical trial.  Extent and ty pe of  work -up m ay vary  by subject’s history , severi ty of liver injury , 
underlying disease, and geography .  
Recommended Evaluation Competing Causes of Abnormal Liver Tests
1st Line Testing
ALT, AST, ALP, TBL, direct bilirubin, GGT, CK Routine follow up 
Thorough history of symptoms, co -existing medical 
conditio ns, concomitant medications, dietary and 
nutritio nal supplements, excessive exercise or muscle 
injury , alcohol consumption, illicit substances .  Systemic infection/ sepsis; ischemic/ congestive 
hepatic injury; gallstone disease; alcoholic liver 
disease; muscle injury/ rhabdomyolysis; 
acetaminoph en toxicity; DILI due to another drug, 
herbal or dietary  supplement .  
Serum CK Muscle injury/rhabdomyolysis a
Anti-HAV (IgM) Acute HAV infection
HBsAg
Anti-HBc IgG, IgMAcute hepatitis B; exacerbation of chronic hepatitis B
Anti-HCV 
HCV RNA (PCR) bAcute hepatitis C c; exacerbation of chronic hepatitis C
Anti-HEV (IgG, IgM), HEV RNA d Acute hepatitis E
ANA, ASMA, quantitative immunoglobulins 
(IgG, IgM, IgA)Autoimmune hepatitis e
Hepatobiliary imaging 
(ultrasonography, CT scan, MRI, MRCP) fBilia ry obstruction; pancreatitis; gallstones; 
portal -vein/ hepatic vein thrombosis; hepatic 
metastasis 
2nd Line Testing
PT-INR For patients with elevated TBL or suspected liver 
failure 
Serological tests for EBV, CMV, HSV 
May need to obtain acute and convalescent serological 
testsHepatic injury caused by CMV, EBV, HSV
EBV -DNA, CMV -DNA, HSV -DNA by PCR .  
Liver biopsy needed to confirm HSVHepatic injury caused by CMV, EBV, HSV
Additional Tests g
Bone specific ALP (ALP fractionation) Differentiate bone from liver origin 
LKM -1 antibody Autoimmune hepatitis
Urinary  ethy lglucuro nide h, 
blood phosphatidylethanol iAlcoholic liver disease
Serum acetaminophen level; 
acetaminophen protein adductsAcetaminophen toxicity
Review of blood pressure, pulse, electrocardiogram, 
echocardiogram, cardiology consultIschemic or congestive hepatic injury 

I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 90
LY3298176Urine toxicology screen Hepatotoxicity due to cocaine, opiates and other illicit 
substances
Anti-HDV Hepatitis D 
Blood or urine cultu res Systemic infection, sepsis
Serum ceruloplasmin, serum copper Slit lamp eyes 
examination for Kayser -Fleischer rings, genetic testingWilson’s disease
Abbreviations:  ALP = alkaline phosphatase; ALT = alanine aminotransferase; ANA =antinuclear antibody; 
anti- =antibody; ASMA =anti-smooth muscle antibody; AST = aspartate aminotransferase; CK = creatinine 
kinase; CMV =cytomegalovirus; CT =computed tomography; DILI = drug -induced liver injury; EBV =Epstein 
Bar Virus; GGT = gamma -glutamyl trans ferase; HAV = hepatitis A virus; HBc =hepatitis B core; 
HBsAg =hepatitis B surface antigen; HBV =hepatitis B virus; HCV =hepatitis C virus; HDV =hepatitis D 
virus; HEV =hepatitis E virus; HSV =herpes simplex virus; Ig =immunoglobulin; INR =interna tional 
normalized ratio; LKM -1 = liver kidney microsomal type 1; MRCP =magnetic resonance 
cholangiopancreatography; MRI =magnetic resonance imaging; PCR =polymerase chain reaction; 
PT-INR =prothrombin time -international normalized ratio; RNA =ribonucl eic acid; TBL =total bilirubin.
aSerum AST typically (although not always) is higher than ALT
bIf anti -HCV positive, HCV RNA is required to confirm HCV infection
cAcute hepatitis C may be anti -HCV negative but HCV RNA positive 
dIf anti -HEV IgM pos itive, consider confirmation with HEV RNA by nested PCR
eA liver biopsy is needed to confirm a diagnosis of autoimmune hepatitis 
fIf cholestatic injury, MRCP may be recommended
gBased on medical history and clinical judgment
hAlcohol consumption in past 3 to 5 days 
iAlcohol consumption in past 3 weeks
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 91
LY3298176Appendix 7. Pancreatic Monitoring
Abbreviations:  CT = computed tomography; L/A = lipase and/or amylase ;MRI = magnetic resonance imaging; 
ULN = upper limit of normal.

I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 92
LY3298176Subjects diagnosed with pancreat itis will be discontinued fro m the study .  Invest igators will be 
responsible for fo llowing, through an appropriate healthcare option, these pancreat itis AEs unt il 
the events resolve or are explained.  Adverse events that meet the diagnostic criteria of acute 
pancreat itis will be captured as serious adverse events (SAEs).  For all other pancreatic AEs 
(such as idiopathic or asymptomat ic pancreat ic enzyme abnormalit ies), the invest igator will be 
responsible for determining the seriousness of the event (AE or SAE) and the relatedness of the 
event to investigational product.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 93
LY3298176Appendix 8. Recommended Laboratory  Testing for 
Hypersensitivity  Events
Lab testing should be performed at the time of a Syst emic Hypersensit ivity Event. Important 
inform ation about why , when, and what to test for are provided below. The m anagement of the 
adverse event may warrant lab testing beyo nd that described below and should be performed as 
clinically indicated.
Laborato ry testing during a Sy stemic Hypersensit ivity Event is notperformed for diagnostic 
purposes. Its intent is several fo ld:
To hel p characteri ze and cl assify  systemic hypersensit ivity reacti ons
To m eet regulatory  expectati ons
To improve subsequent clinical management by  helping to di stinguish between the 
various mechanist ic bases of anaphylaxis
When Should Labs Be Obtained?
In the presence of generalized urticaria orif anaphylaxis is suspected
After the subject has been stabilized, obtain a sample within 1 to 2 hours of the event ; 
however , samples may  be obtained as late as 12 hours after the event as analy tes can 
remain altered for an extended period of time. Record the time at which the sample was 
collected.
Obtain a fo llow-up sam ple at the next regularly scheduled visit or after 4 weeks, 
whichever i s later.
What Labs* Should Be Obtained?
Tryptase**
ADA and tirzepat ide concentrati on (PK)
oADA testing should include drug- specific immunoglobulin ( Ig)E or the basophil 
activat ion test (BAT)#. These tests are not routinely available and need to be 
developed for individual mo lecules based on their evo lving safet y profile.  
Samples are collected, and testing conducted once the assay  is available, as 
appropriate. Please consult an immunologist wit hin GPS for further guidance.
Com plement
oC3a and C5a
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 94
LY3298176Cytokines
oIL‐6, IL‐1 β, IL‐10 (or any  cytokine panel  that includes these 3 cy tokines)
* T hese labs are bundled in the Clinical Laboratory  Operati ons Hypersensit ivity Lab Testing 
Kit.  
** If a try ptase sample is obtained more than 2 hours after the event (i .e., wi thin 2 to 12 hours), 
or is not obtained because more than 12 hours have lapsed since the event, obtain urine for 
N-methylhistamine (NMH) testing .  Note that for try ptase serum  samples obtained w ithin 
2to12 hours of the event, urine NMH testing is performed in addit ion to try ptase testing .  
Collect the first void urine fo llowing the event .  Obtain a fo llow-up urine for NMH testing 
at the next regularly scheduled visit or after 4 weeks, whichever is later.
# The BAT i s an in vit rocell based assay  that only  requi res a serum  sample .  It is a surrogate 
assay for drug specific IgE but is not specific for IgE.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 95
LY3298176Appendix 9. Protocol A mendment I8F-MC-GPHH( f) 
Summary  -Effect of Tirzepatide on Energy  Intake and 
Appetite-and Reward -Related Brain A reas in 
Overweight/Obese Subjects:  A  Placebo -Controlled 
6-Week Study  with Functional MRI
Overview
Protocol  I8F-MC-GPHH, Effect of Tirzepat ide on Energy Intake and Appet ite-and 
Reward -Related Brain Areas in Overweight/Obese Subjects:  A Placebo -Controlled 6 -Week 
Study  with Functi onal MRI ,has been amended.  The new protocol is indicated by  Amendment 
(f) and will  be used to conduct the study  in place of any preceding versio n of the protocol.
This amendment is considered a nonsubstantial protocol amendment.
The overall changes and rationale for the changes made to this protocol are as fo llows:
Appendix 5 was updated to include language on 
othe types of scanner s on which MRI scanning will occur to specify the different 
scanners used across the different study  sites and,
othe hand squeezing task following the food image task to evaluate inter-scanner 
variabilit yacross the different scanners. The hand squeezing task produces 
consistent patterns of motor cortex activat ion in the brain ,independent of scanner
type.
The hand squeezing task will be used to ensure that the fMRI data from  all 
sites can be analyzed collect ively at the end of the study .
oThe description of preprocessing of fMRI data was deleted because it will be 
performed by an external  imaging laboratory  services provi der.
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 96
LY3298176Revised Protocol Sections
Note: All deletions have been ident ified by strikethroughs .
All additions have been ident ified by the use of underscore .
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 97
LY3298176Appendix 5
5.2 Magnetic Resonance Imaging
Funct ionalneuroimaging, in the forms of BOLD fMRI will be used to assess brain response 
patterns to food and non-food images . The MRI scanning will occur on different scanners such 
asa 3T General Electric Discovery 750W wit h 32-channel head co il, a 3T Ge neral Electric 
Discovery  750 wi th 32-channel head coil, a 3T Siemens Prisma with a 64- channel head co il, or a 
3T Philips Achieva with a 32 -channel head coil . Functi onal neuroimaging sessio n will be 
conducted after participants fast overnight for at least 8 hours (ten Kulve et al. 2016).   
Subjects will be required to complete the food image task during the BOLD fMRI scan.  The 
food image task was developed using images fro m the Food- pic database (Blechert et al. 2014) .
Briefly, 90food images across sweet and savory tastes, high -and low -energy  densi ty, and varied 
macronutrient composit ion, were included along wit h 15 images o f non- food obj ects (e.g.
everyday househo ld objects ). This results in 105 images in total.
For the purposes of evaluat ing inter-scanner variabilit y to ensure that the fMRI data from all sites 
can be analyzed co llectively at the end of the study, subjects will be required to complete a 
bilateral  hand squeeze motor task during the BOLD fMRI scan, consist ing of 4blocks after the 
food ima ge task. Each block will consist of 30 seconds of bilateral hand squeezing fo llowed by  
30 seconds of rest (around 3 minutes total run t ime).
BOLD fMRI Data Processing
The BOLD fMRI acquisit ion parameters include repetit ion time of 3000 ms, echo time o f 30ms, 
flip angle of 90 °, slice thickness of 3.5 mm, and 64× 64 image matrix .  
As in prior work (King et al. 2018), a T1-weighted magnet ization-prepared 180° radio -frequency 
pulses and rapi d gradi ent-echo ( MPRAGE )will be collected as an anatomical referenc e for 
funct ional data .  
Preprocessing o f fMRI data will be done by an external imaging laboratory  services provi der.in 
SPM8 includes slice -timing correction, head -motion correcti on, sm oothing, and warping to a 
standard coordinate frame.  Time points with head rotati on greater than 2 or translation greater 
than 2 mm will be removed.  Data will be entered into a first -level voxel-wise analysis wit h each 
trial modeled as a boxcar funct ion that covers the period of time when the l arge image i s viewed.  
The boxcar function is convolved with the canonical hemodynamic response function. 
Funct ional scans will be analyzed in the context of the general linear model. 
For the hand squeezing fMRI task, BOLD contrasts of hand squeezing versus resting wit hin 
bilateral  som atom otor ROIs will be calculated.  For the food image fMRI task, h Highly palatable 
food (HF -HS, HF -HCCHO), not highly  palatable foods ( low fat -low carbohy drate -high 
protein LF-LCCHO- HP), and non -food obj ect bl ocks will  be modeled. To assess brain act ivation 
related to vi ewing food pi ctures, the con trast between highly  palatable foods and non -food 
objects will be computed. Addit ionally , the contrast between h ighly palatable foods and not 
highly  palatable foods as well as the contrast between not highly palatable foods and non -food 
objects m ay be com puted. Contrasts between each specific food category  and non -food obj ects 
I8F-MC-GPHH(f) Clinical Pharmacology Protocol Page 98
LY3298176may also be computed if deemed necessar y. Average BOLD contrast in each of 9 areas 
associ ated to brain reward will be reported (insula, medial frontal gy rus, superi or tem poral  gyrus, 
precentral  gyrus, cingulate gyrus, hippocam pus, putam en, orbi tofrontal  cortex, and ventral 
striatum ).
Leo Document ID = a44bff92-a78c-493a-b066-c0ef15232beb
Approver: 
Approval Date & Time: 08-Oct-2021 12:53:16 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 08-Oct-2021 15:32:30 GMT
Signature meaning: Approved
PPD
PPD